https://trial.medpath.com/news/5539b5c641f988b5/stimulating-a-nerve-the-long-winding-road-of-vagus-nerve-stimulation-as-a-treatment 2024-12-13T21:14:26+00:00 weekly 0.7 https://trial.medpath.com/news/c07bac6440e9d3a7/study-finds-sglt-2-inhibitor-may-slow-progression-of-diabetic-retinopathy-in-patients-with 2024-12-13T21:14:09+00:00 weekly 0.7 https://trial.medpath.com/news/b9d6f61ffaaf2e79/fda-revokes-emergency-use-authorization-eua-for-bebtelovimab-for-the-treatment-of-covid-19 2024-12-13T21:12:25+00:00 weekly 0.7 https://trial.medpath.com/news/136f717f3a7d0925/fda-revokes-eua-for-sotrovimab-for-the-treatment-of-covid-19 2024-12-13T21:12:24+00:00 weekly 0.7 https://trial.medpath.com/news/85235573a6adf52e/giroctocogene-fitelparvovec-prevents-hem-a-bleeds-new-trial-data 2024-12-13T20:41:13+00:00 weekly 0.7 https://trial.medpath.com/news/5581024a66e89684/gileads-seladelpar-receives-positive-chmp-opinion-for-primary-biliary-cholangitis 2024-12-13T20:31:11+00:00 weekly 0.7 https://trial.medpath.com/news/81266fe197443885/niraparib-dostarlimab-shows-promise-in-brca-er-her2-breast-cancer 2024-12-13T20:29:57+00:00 weekly 0.7 https://trial.medpath.com/news/c2f4370a0666e3e6/say-that-again-cooling-devices-may-prevent-hearing-loss-inventum 2024-12-13T20:18:29+00:00 weekly 0.7 https://trial.medpath.com/news/111345f83313e26b/fda-revokes-eua-for-evusheld-tixagevimab-co-packaged-with-cilgavimab 2024-12-13T20:12:00+00:00 weekly 0.7 https://trial.medpath.com/news/fbe3125d83889146/fda-approves-new-oral-antibiotic-to-treat-uncomplicated-utis-drug-discovery-news 2024-12-13T20:05:16+00:00 weekly 0.7 https://trial.medpath.com/news/a7b43071bbeba37f/perioperative-atezolizumab-falls-short-in-tnbc-targeted-oncology 2024-12-13T19:58:39+00:00 weekly 0.7 https://trial.medpath.com/news/d08ca7bc02b39c52/hiv-drug-based-in-research-by-sundquist-lab-is-sci-newswise 2024-12-13T19:56:54+00:00 weekly 0.7 https://trial.medpath.com/news/bfe50a2c77bd8631/response-rates-were-improved-for-camrelizumab-chemo-vs-chemo-in-tnbc 2024-12-13T19:47:08+00:00 weekly 0.7 https://trial.medpath.com/news/30c429c4ab2be1d5/zest-trial-offers-insights-for-using-ctdna-to-predict-breast-cancer-recurrence 2024-12-13T19:19:09+00:00 weekly 0.7 https://trial.medpath.com/news/b592caf5829212a8/talquetamab-step-up-dosing-strategies-and-crs-monitoring-targeted-oncology 2024-12-13T19:18:27+00:00 weekly 0.7 https://trial.medpath.com/news/c2d68c02d65b4339/csl-receives-positive-chmp-opinion-for-garadacimab-in-hereditary-angioedema-hae 2024-12-13T18:40:12+00:00 weekly 0.7 https://trial.medpath.com/news/316e9343feade98c/chmp-recommends-approval-of-galderma-s-nemolizumab-for-moderate-to-severe-atopic 2024-12-13T18:18:40+00:00 weekly 0.7 https://trial.medpath.com/news/c24eb936ae263d41/orca-t-leads-to-retrospective-os-improvement-in-high-risk-hematologic-malignancies 2024-12-13T18:13:33+00:00 weekly 0.7 https://trial.medpath.com/news/646251b13a656596/high-dose-bi655064-shows-promising-results-in-improving-renal-outcomes-for-people 2024-12-13T17:53:19+00:00 weekly 0.7 https://trial.medpath.com/news/a3c88302b1814f68/inupadenant-deprioritised-by-iteos-in-favour-of-pipeline-tigit-therapy 2024-12-13T17:44:15+00:00 weekly 0.7 https://trial.medpath.com/news/216ce318a1998dd8/action-centers-collaborate-with-johnson-johnson-medtech-to-secure-fda-labeling-for 2024-12-13T17:43:21+00:00 weekly 0.7 https://trial.medpath.com/news/9c724d829e9d2d18/cancer-drug-and-medical-trials-revolutionizing-care-for-patients-in-brampton-and-beyond 2024-12-13T17:42:01+00:00 weekly 0.7 https://trial.medpath.com/news/d63edc82bc14dcd6/ideaya-biosciences-stock-hits-52-week-low-at-25-16-investing-com 2024-12-13T17:35:51+00:00 weekly 0.7 https://trial.medpath.com/news/febacc16e882918a/tam-anh-general-hospital-joins-global-effort-to-advance-cancer-treatment-with-vista-1-clinical-trial 2024-12-13T17:28:05+00:00 weekly 0.7 https://trial.medpath.com/news/e371d1cc57e7f7f4/eu-drugs-regulator-backs-mounjaro-s-sleep-apnea-use-without-fresh-approval-for-lilly 2024-12-13T17:24:39+00:00 weekly 0.7 https://trial.medpath.com/news/2e2238ea5780b165/postoperative-radiation-improves-hrqol-over-endocrine-therapy-in-breast-cancer 2024-12-13T17:18:17+00:00 weekly 0.7 https://trial.medpath.com/news/b2d8ce1b107c7553/repare-therapeutics-shares-drop-38-following-phase-1-trial-results-yahoo-finance 2024-12-13T17:10:08+00:00 weekly 0.7 https://trial.medpath.com/news/79979222f6bbc3d5/sibylle-loibl-on-primary-results-of-the-randomized-phase-iii-padma-study-in-her2 2024-12-13T16:41:36+00:00 weekly 0.7 https://trial.medpath.com/news/05ceef8b46fb0007/european-commission-approves-imetelstat-for-transfusion-dependent-anemia-in-lower-risk-mds 2024-12-13T16:36:45+00:00 weekly 0.7 https://trial.medpath.com/news/9dccc90d6e33f5cb/pharmaceutical-business-updates-from-november-2024 2024-12-13T16:32:52+00:00 weekly 0.7 https://trial.medpath.com/news/4105814175bec60d/dream-hf-trial-sheds-positive-light-on-revascor-for-ischemic-hf-clinical-trials-arena 2024-12-13T16:29:33+00:00 weekly 0.7 https://trial.medpath.com/news/d3a878cd20a7d75d/targeting-peptide-antigens-using-a-multiallelic-mhc-i-binding-system-nature-biotechnology 2024-12-13T16:19:47+00:00 weekly 0.7 https://trial.medpath.com/news/6bec80318aed275f/intermittent-or-continuous-panitumumab-plus-folfiri-in-first-line-treatment-of-ras-and 2024-12-13T15:41:36+00:00 weekly 0.7 https://trial.medpath.com/news/ffca4c04848158ce/100-mg-bezuclastinib-improves-symptoms-biomarkers-in-non-advanced-systemic-mastocytosis 2024-12-13T15:21:46+00:00 weekly 0.7 https://trial.medpath.com/news/23180f9937e9c41c/brain-tumors-hijack-circadian-rhythms-to-accelerate-growth-inside-precision-medicine 2024-12-13T15:15:18+00:00 weekly 0.7 https://trial.medpath.com/news/f4c5f860305abdcb/walgreens-boots-alliance-inc-wba-launches-clinical-trials-patient-advisory-board 2024-12-13T15:12:34+00:00 weekly 0.7 https://trial.medpath.com/news/a8bc897fd5ec1b6b/fda-clears-splicebio-s-ind-application-to-begin-stargardt-disease-therapy-trial 2024-12-13T15:10:01+00:00 weekly 0.7 https://trial.medpath.com/news/ebadbe838ace0489/launch-of-largest-ever-study-tracking-chikungunya-burden-in-east-africa 2024-12-13T14:46:20+00:00 weekly 0.7 https://trial.medpath.com/news/8927a48a0a25992b/stockport-grandad-free-from-blood-cancer-after-being-on-a-clinical-trial-at-the-christie 2024-12-13T14:29:58+00:00 weekly 0.7 https://trial.medpath.com/news/71ab0a567f32c89a/single-cell-rna-sequencing-reveals-transcriptional-changes-in-circulating-immune-cells 2024-12-13T14:16:36+00:00 weekly 0.7 https://trial.medpath.com/news/1a4a6b1b6a755884/maic-points-to-improved-os-with-momelotinib-in-ruxolitinib-pretreated-myelofibrosis 2024-12-13T14:06:51+00:00 weekly 0.7 https://trial.medpath.com/news/453fe00efe280181/eli-lilly-s-omvoh-scores-landmark-chmp-backing-for-crohn-s-disease-first-to-show-stock-titan 2024-12-13T13:51:45+00:00 weekly 0.7 https://trial.medpath.com/news/922ee847b73de607/innovative-biologic-prefilled-syringe-approved-in-eu-european-pharmaceutical-review 2024-12-13T13:36:34+00:00 weekly 0.7 https://trial.medpath.com/news/dede8dc9be27add0/ub-studies-on-ms-patients-reveal-how-paramagnetic-rim-lesions-evolve-what-they-mean-for 2024-12-13T13:26:15+00:00 weekly 0.7 https://trial.medpath.com/news/ff58dd280978c3ab/multimodal-machine-learning-model-effective-at-predicting-response-to-cdk4-6-inhibitors 2024-12-13T13:19:11+00:00 weekly 0.7 https://trial.medpath.com/news/fa4c3776ad259b41/ben-samelson-jones-md-phd-on-confirming-the-safety-of-pfizer-s-hemophilia-b-gene 2024-12-13T13:07:49+00:00 weekly 0.7 https://trial.medpath.com/news/be5ae757b60cbcfd/novavax-advances-corporate-growth-strategy-through-sanofi-partnership-including 2024-12-13T13:04:54+00:00 weekly 0.7 https://trial.medpath.com/news/4657472d5d7962d8/dcgi-pushes-fast-track-approval-for-rare-disease-drugs-prioritizes-patient-access 2024-12-13T12:58:56+00:00 weekly 0.7 https://trial.medpath.com/news/727b7a5fd673f824/newron-and-ea-pharma-a-subsidiary-of-eisai-co-ltd-announce-license-agreement-for 2024-12-13T12:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/6a57c0d0c6b24644/sec-form-10-q-filed-by-galera-therapeutics-inc-quantisnow 2024-12-13T12:31:16+00:00 weekly 0.7 https://trial.medpath.com/news/6aeb53cd9a69f5a6/geron-corp-gern-receives-positive-chmp-opinion-for-rytelo-in-t-gurufocus 2024-12-13T12:13:47+00:00 weekly 0.7 https://trial.medpath.com/news/4fb62ba757a42e49/the-board-of-directors-decision-on-a-new-execution-strategy-and-prioritisation-of-clinical 2024-12-13T11:27:18+00:00 weekly 0.7 https://trial.medpath.com/news/d2345d7c6c9d988e/multispecific-antibodies-market-set-to-exceed-40-billion-as-next-generation-cancer-therapies-advance 2024-12-13T11:24:39+00:00 weekly 0.7 https://trial.medpath.com/news/8c27bee34f12dd53/cost-barriers-lead-to-medication-non-adherence-in-17-8-of-us-asthma-patients-study-reveals 2024-12-13T11:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/45e863eade559e8f/diamyd-medical-agreement-with-fda-on-factors-for-accelerated-approval-process 2024-12-13T10:30:07+00:00 weekly 0.7 https://trial.medpath.com/news/b3670e4ffabc7c0d/ionis-has-much-riding-on-drug-approval-and-major-strategic-shift-stat-news 2024-12-13T09:34:07+00:00 weekly 0.7 https://trial.medpath.com/news/f79f018cd91667ae/tyra-300-shows-promise-in-urothelial-cancer-treatment-with-projected-63m-revenue-by-2036 2024-12-13T09:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/5484c97506a1b86f/adalimumab-biosimilars-drive-45-drop-in-net-spending-despite-limited-market-share 2024-12-13T08:53:36+00:00 weekly 0.7 https://trial.medpath.com/news/6df0653be6a1fd85/phase-iii-randomized-trial-complementary-analysis-of-immune-persistence-3-6-years-after-priming 2024-12-13T08:34:07+00:00 weekly 0.7 https://trial.medpath.com/news/555feeba44f78ca6/less-frequent-elfabrio-ert-regimen-for-fabry-up-for-eu-approval 2024-12-13T07:38:49+00:00 weekly 0.7 https://trial.medpath.com/news/9f2b19b2cb030cc7/sanofi-s-tolebrutinib-gets-fda-breakthrough-therapy-designation-for-nrspms 2024-12-13T07:29:15+00:00 weekly 0.7 https://trial.medpath.com/news/c2fbd8237885531e/rezolute-s-clinical-progress-and-market-potential-highlighted-in-swot-analysis 2024-12-13T06:11:00+00:00 weekly 0.7 https://trial.medpath.com/news/2ef54cf961b005ba/missouri-healthcare-system-shows-resilience-amid-historic-medicaid-expansion-survey-reveals 2024-12-13T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a90dbe71d4369c94/2024-s-most-impactful-gene-therapy-developments-from-cost-challenges-to-access-solutions 2024-12-13T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8af44e4d1add8a97/accropeutics-inc-announces-u-s-fda-clearance-of-ind-application-for-ripk2-inhibitor-ac-101 2024-12-13T05:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/2c8c6155a38d36bd/biomarker-guided-therapies-transform-treatment-landscape-across-multiple-cancers 2024-12-13T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/daa75b8184748a74/briacell-2024-sabcs-r-poster-highlights-ability-of-bria-imttm-regimen-to-increase-cancer-fighting-immune-cells-in-metastatic-breast-cancer 2024-12-13T04:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/8bffd5bdb8b6c5fa/novel-treatment-strategies-emerge-for-egfr-mutated-nsclc-as-amivantamab-shows-promise 2024-12-13T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4171ca256429c09f/bristol-myers-faces-lawsuit-from-padlock-therapeutics-investors-over-milestone-payment-dispute 2024-12-13T03:46:00+00:00 weekly 0.7 https://trial.medpath.com/news/0ccc67d2f3e55c00/alphamab-oncology-presents-the-phase-ii-clinical-data-of-kn046-in-combination-with 2024-12-13T03:25:34+00:00 weekly 0.7 https://trial.medpath.com/news/b50619066b23b590/abbvie-acquires-nimble-therapeutics-for-200m-expanding-oral-immunology-pipeline 2024-12-13T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6ac9d5e5c13201d5/solventum-pioneers-novel-tooth-based-randomization-approach-in-dental-clinical-trials-using-zelta-platform 2024-12-13T02:46:53+00:00 weekly 0.7 https://trial.medpath.com/news/d45bd264384730ab/study-reveals-lack-of-clinical-evidence-behind-popular-dietary-supplements-health-claims 2024-12-13T02:24:20+00:00 weekly 0.7 https://trial.medpath.com/news/0c8f6444ddfa5a45/nyxoah-expands-global-reach-genio-neurostimulation-therapy-for-osa-launches-in-middle-east-and-england 2024-12-13T01:49:32+00:00 weekly 0.7 https://trial.medpath.com/news/7aa6e3f16b56860c/most-patients-with-intermediate-risk-breast-cancer-may-safely-avoid-chest-wall-irradiation 2024-12-13T01:34:09+00:00 weekly 0.7 https://trial.medpath.com/news/a6bec465a088d191/ars-pharmaceuticals-announces-filings-for-approval-of-neffy-r-in-china-japan-and-australia 2024-12-13T01:33:47+00:00 weekly 0.7 https://trial.medpath.com/news/4e83ae32929b840b/interview-mediwhale-pushes-for-fda-approval-to-bring-ai-retinal-scan-to-us-cardiovascular-kbr 2024-12-13T01:01:59+00:00 weekly 0.7 https://trial.medpath.com/news/d07a4887fcff751d/fda-revokes-euas-for-four-monoclonal-antibody-products 2024-12-13T00:11:00+00:00 weekly 0.7 https://trial.medpath.com/news/2596399c4dd12551/clinical-and-biomarker-analyses-of-shr-1701-combined-with-famitinib-in-patients-with-nature 2024-12-13T00:07:57+00:00 weekly 0.7 https://trial.medpath.com/news/a1b284983a571787/the-daily-hit-december-12-2024-green-market-report 2024-12-13T00:06:05+00:00 weekly 0.7 https://trial.medpath.com/news/b910d37cfd621741/university-of-wollongong-secures-500k-grant-to-advance-resectassisttm-cancer-device-for-pancreatic-tumors 2024-12-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a4c57299c73a4475/solid-biosciences-positioned-for-next-gen-duchenne-muscular-dystrophy-treatment-success-analyst 2024-12-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e4daf4d7b2ba2254/bicycle-therapeutics-announces-data-updates-across-zelenectide-pevedotin-program-and 2024-12-12T23:41:49+00:00 weekly 0.7 https://trial.medpath.com/news/9832210bbf8d89f0/2024-sabcs-results-unveiled-for-the-phase-iii-study-of-disitamab-vedotin-in-treating 2024-12-12T23:40:43+00:00 weekly 0.7 https://trial.medpath.com/news/b7d7b5c4b91b8fee/takeda-spotlights-high-value-late-stage-pipeline-accelerating-the-development-of-biospace 2024-12-12T23:29:40+00:00 weekly 0.7 https://trial.medpath.com/news/97b462bd2e639593/keros-shares-collapse-on-unanticipated-setback-for-lung-disease-drug-biopharma-dive 2024-12-12T23:15:58+00:00 weekly 0.7 https://trial.medpath.com/news/dd6b54a617198851/scott-tagawa-md-highlights-phase-3-trial-of-177lu-tlx591-in-mcrpc-urology-times 2024-12-12T23:03:35+00:00 weekly 0.7 https://trial.medpath.com/news/ea9bc9fc4b22d867/pfizer-s-novel-mash-treatment-combination-clesacostat-ervogastat-projects-16m-revenue-by-2036 2024-12-12T22:59:33+00:00 weekly 0.7 https://trial.medpath.com/news/8a530b191411fe89/improving-access-to-nivolumab-by-lowering-age-restrictions-in-clinical-trial 2024-12-12T22:26:59+00:00 weekly 0.7 https://trial.medpath.com/news/c1be52f51a9a2816/corcept-s-als-drug-trial-disappoints-but-zero-deaths-in-high-dose-group-firstword-pharma 2024-12-12T21:43:07+00:00 weekly 0.7 https://trial.medpath.com/news/bea2578ade93e126/repare-therapeutics-announces-positive-results-of-the-lunresertib-and-camonsertib-stock-titan 2024-12-12T21:27:10+00:00 weekly 0.7 https://trial.medpath.com/news/9fdd42c39220dfa7/clinical-trials-at-the-neuro-target-myotonic-dystrophy-mcgill-reporter 2024-12-12T21:18:48+00:00 weekly 0.7 https://trial.medpath.com/news/6995ba298700766e/corcept-s-korlym-shows-breakthrough-results-in-phase-4-diabetes-cushing-s-trial-hits 2024-12-12T21:15:40+00:00 weekly 0.7 https://trial.medpath.com/news/ecfdcb62d3dab67a/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-globenewswire 2024-12-12T21:11:48+00:00 weekly 0.7 https://trial.medpath.com/news/1c2a2db585d17501/ascendis-pharma-s-transcon-hgh-scores-fda-filing-acceptance-after-superior-stock-titan 2024-12-12T21:08:41+00:00 weekly 0.7 https://trial.medpath.com/news/8f597aa1c2cd2f80/ongoing-trials-may-elucidate-mosunetuzumab-efficacy-in-follicular-lymphoma 2024-12-12T21:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/fdc000faea3e29a6/innocan-pharma-provides-its-annual-state-of-research-and-development-update-for-2024 2024-12-12T21:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/1692ef164076b500/defloria-s-advances-cannabis-based-autism-drug-through-early-trial-green-market-report 2024-12-12T20:20:23+00:00 weekly 0.7 https://trial.medpath.com/news/bcd988d10d581b05/pitt-led-study-likely-to-change-standard-of-care-strokes-upmc 2024-12-12T20:19:58+00:00 weekly 0.7 https://trial.medpath.com/news/884f6f70a61da428/online-vs-face-to-face-pulmonary-rehabilitation-for-copd-patients-a-randomized-controlled-trial 2024-12-12T20:12:00+00:00 weekly 0.7 https://trial.medpath.com/news/88db0c8cbf19b504/shine-study-developing-an-intervention-for-safe-hospital-insulin-use-for-older-or-frail-adults-plos 2024-12-12T20:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/c7a18c65a5c8d239/sean-m-healey-amg-center-announces-updates-to-healey-als-platform-trial-master-protocol 2024-12-12T19:26:26+00:00 weekly 0.7 https://trial.medpath.com/news/95ab0276056d3d25/new-partnership-between-cytophage-orthopedic-innovation-centre-targets-prosthetic 2024-12-12T18:50:13+00:00 weekly 0.7 https://trial.medpath.com/news/9e3f4be8a0e08a2c/targeted-alpha-therapy-market-clinical-trials-proprietary-technologies-insight-biospace 2024-12-12T18:37:25+00:00 weekly 0.7 https://trial.medpath.com/news/6dedddda09fbb085/autologous-stem-cell-transplantation-may-not-improve-survival-in-patients-with-mcl 2024-12-12T18:35:56+00:00 weekly 0.7 https://trial.medpath.com/news/0af5a4d4e7d5c4af/private-medicare-plans-required-to-cover-biogen-s-als-drug-says-us-agency 2024-12-12T17:51:00+00:00 weekly 0.7 https://trial.medpath.com/news/b9f6fa8c065f9251/abbvie-completes-acquisition-of-aliada-therapeutics-pharmaceutical-executive 2024-12-12T17:14:07+00:00 weekly 0.7 https://trial.medpath.com/news/01547ee8a0ee7175/kidney-compass-parasol-findings-and-implications-for-fsgs-hcplive 2024-12-12T17:10:09+00:00 weekly 0.7 https://trial.medpath.com/news/c75103023b37d08a/commands-trial-luspatercept-long-term-transfusion-benefit-compared-with-epoetin-alfa 2024-12-12T16:55:00+00:00 weekly 0.7 https://trial.medpath.com/news/88f90de27e35d2c2/highest-risk-cll-patients-may-benefit-from-car-t-with-btk-inhibitor-clinical-trials-arena 2024-12-12T16:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/a059a0477d54c4b3/a-randomized-phase-iii-clinical-trial-in-colon-cancer-company-announcement-markets-data 2024-12-12T16:13:17+00:00 weekly 0.7 https://trial.medpath.com/news/a0b7f253852e978c/sobi-announces-fda-acceptance-of-new-drug-application-for-avatrombopag-doptelet 2024-12-12T15:57:39+00:00 weekly 0.7 https://trial.medpath.com/news/4f27faa344024eee/seaport-therapeutics-sees-success-with-allopregnanolone-prodrug-clinical-trials-arena 2024-12-12T15:43:11+00:00 weekly 0.7 https://trial.medpath.com/news/d4a0bfcf4aed0348/light-therapy-trial-shows-feasibility-of-home-studies-in-parkinson-s 2024-12-12T15:17:32+00:00 weekly 0.7 https://trial.medpath.com/news/6bad80fdeb218d72/december-12-2024-another-year-of-innovations-and-insights-from-the-nih-pragmatic-trials 2024-12-12T15:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/e90447bd1ab1c91b/pdc-line-pharma-presents-primary-clinical-results-from-phase-i-ii-trial-on-pdc-lung01 2024-12-12T14:58:56+00:00 weekly 0.7 https://trial.medpath.com/news/4ce887c98821e46f/phase-iii-patina-study-shows-hope-for-hr-her2-cancer-mirage-news 2024-12-12T14:58:46+00:00 weekly 0.7 https://trial.medpath.com/news/03070f9ce07a0811/egetis-receives-positive-chmp-opinion-for-emcitate-r-tiratricol-for-the-treatment-of-mct8-deficiency 2024-12-12T14:44:58+00:00 weekly 0.7 https://trial.medpath.com/news/420e8da06033bbef/dr-jitendra-announces-successful-gene-therapy-trial-for-haemophilia-blood-disorder 2024-12-12T14:41:40+00:00 weekly 0.7 https://trial.medpath.com/news/cada5a0a21b0393c/kiromic-biopharma-reports-32-decrease-in-tumor-volume-eight-months-post-treatment 2024-12-12T14:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/2d72c196047c26d3/cel-sci-s-cancer-drug-multikine-secures-fda-approval-for-pivotal-study-after-73 2024-12-12T14:34:08+00:00 weekly 0.7 https://trial.medpath.com/news/c148a89784f51078/europe-allows-novo-to-include-reduction-of-kidney-disease-in-ozempic-label 2024-12-12T14:33:00+00:00 weekly 0.7 https://trial.medpath.com/news/29a4d3b35ff34aa8/inupadenant-shows-promise-in-nsclc-phase-2-trial-results-investing-com 2024-12-12T14:31:36+00:00 weekly 0.7 https://trial.medpath.com/news/32b4fe10a9371704/alx-oncology-to-host-virtual-event-on-new-clinical-data-from-breast-cancer-study 2024-12-12T14:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/36e346d8fc731f2a/u-s-fda-expands-indication-for-impella-heart-pumps-to-treat-pediatric-patients-pr-newswire 2024-12-12T14:19:59+00:00 weekly 0.7 https://trial.medpath.com/news/58da36b2683cbec8/uae-based-biotech-biosapien-secures-5-5-million-pre-series-a-wamda 2024-12-12T14:19:25+00:00 weekly 0.7 https://trial.medpath.com/news/448a00a98c6b33e4/aptevo-s-aml-drug-trial-hits-100-remission-rate-complete-cancer-cell-elimination-in 2024-12-12T14:16:13+00:00 weekly 0.7 https://trial.medpath.com/news/bf9b7beac86ed98c/curegene-received-clinical-trial-approval-in-china-for-cg-0255-for-injection 2024-12-12T14:14:54+00:00 weekly 0.7 https://trial.medpath.com/news/1f3f9928a0361a4c/study-finds-quality-of-life-maintained-with-active-monitoring-for-dcis 2024-12-12T14:10:31+00:00 weekly 0.7 https://trial.medpath.com/news/9644e91ca3ceef67/momelotinib-shows-real-world-improvements-in-anemia-symptoms-and-spleen 2024-12-12T14:06:12+00:00 weekly 0.7 https://trial.medpath.com/news/dea1e45679d6bac5/iteos-therapeutics-presents-interim-a2a-005-clinical-trial-data-translational-and 2024-12-12T14:04:26+00:00 weekly 0.7 https://trial.medpath.com/news/6d2c736495f3c53c/alzamend-neuro-reports-second-quarter-2025-financial-results-and-provides-update-on 2024-12-12T13:52:44+00:00 weekly 0.7 https://trial.medpath.com/news/670fa9bda07ee1fc/sk-bioscience-receives-approval-for-global-clinical-trials-of-mrna-japanese-encephalitis 2024-12-12T13:45:30+00:00 weekly 0.7 https://trial.medpath.com/news/41e211190c6b23a5/knight-therapeutics-announces-regulatory-approval-of-tavalisse-r-in-mexico 2024-12-12T13:09:48+00:00 weekly 0.7 https://trial.medpath.com/news/aef613a3848e0757/regeneron-s-r-d-approach-scores-dual-wins-against-alexion-s-ultomiris-and-in-lymphoma 2024-12-12T12:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/1f8f4e3954980b18/keros-therapeutics-halts-dosing-in-phase-2-trial-of-cibotercept-combination-in-pah 2024-12-12T12:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/c535490c2d8de3d1/avextra-supports-first-fully-eu-funded-psilocybin-therapy-globenewswire 2024-12-12T12:11:09+00:00 weekly 0.7 https://trial.medpath.com/news/6b01f0bc32e7f2b4/ryvu-therapeutics-provides-an-update-on-rvu120-phase-ii-program-pr-newswire 2024-12-12T11:22:05+00:00 weekly 0.7 https://trial.medpath.com/news/e8232d0b52df3336/ditch-that-itch-early-findings-offer-hope-for-skin-issues-like-rosacea 2024-12-12T11:12:03+00:00 weekly 0.7 https://trial.medpath.com/news/f3ec7b544c7bc0dd/blue-lake-biotechnology-reports-additional-promising-clinical-data-from-ongoing-pediatric 2024-12-12T11:10:23+00:00 weekly 0.7 https://trial.medpath.com/news/83beead381540659/revbio-receives-both-fda-approval-to-expand-its-clinical-trial-and-cms-reimbursement 2024-12-12T10:27:45+00:00 weekly 0.7 https://trial.medpath.com/news/cb765c2dd83862b0/hvivo-unveils-key-covid-19-biomarker-insights-from-human-challenge-study-vox-markets 2024-12-12T10:06:02+00:00 weekly 0.7 https://trial.medpath.com/news/0f8a8c8142520f3d/medicare-drug-price-negotiations-show-limited-impact-on-innovation-study-reveals 2024-12-12T09:12:23+00:00 weekly 0.7 https://trial.medpath.com/news/972f067ef6ab824f/rna-specialist-proqr-therapeutics-nv-bags-us-8-1m-funding-european-biotechnology 2024-12-12T08:59:46+00:00 weekly 0.7 https://trial.medpath.com/news/8b6f39403725d0c8/caris-life-sciences-publishes-large-scale-study-demonstrating-the-critical-role-of-next 2024-12-12T08:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/d275332e722e5cc1/corcept-announces-results-from-phase-2-study-of-dazucorilant-in-patients-with-biospace 2024-12-12T06:49:07+00:00 weekly 0.7 https://trial.medpath.com/news/b55b59d0fe738349/research-scientists-ask-gov-t-to-approve-new-drugs-with-highest-efficacy-of-preventing-hiv 2024-12-12T06:26:46+00:00 weekly 0.7 https://trial.medpath.com/news/8f9fcd0f9923bf6d/tils-assessment-emerges-as-powerful-tool-for-personalizing-breast-cancer-treatment-decisions 2024-12-12T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8bfce8e1fecde8a3/douglas-tsao-maintains-buy-rating-on-xenon-pharmaceuticals-azetukalner 2024-12-12T05:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/c6782241b90ee51d/absci-advances-in-ai-driven-drug-development-and-pipeline-updates-at-2024-r-d-day 2024-12-12T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5315ac583fb99e01/leicester-patients-to-get-early-access-to-potentially-life-changing-treatments-as-new-funding 2024-12-12T04:31:08+00:00 weekly 0.7 https://trial.medpath.com/news/b69eaab723cb6bc2/hutchmed-announces-breakthrough-therapy-designation-in-china-for-orpathys-r-and 2024-12-12T04:15:37+00:00 weekly 0.7 https://trial.medpath.com/news/1ad41771feb501b1/the-vegf-x-pd-l-1-pipeline-is-growing-and-tnbc-may-benefit-biocentury 2024-12-12T03:26:46+00:00 weekly 0.7 https://trial.medpath.com/news/97b12decff16a8bf/prospect-lung-trial-aims-to-improve-treatment-for-patients-with-resectable-non-small-cell 2024-12-12T03:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/37a17cb80fa8bb29/doubts-over-landmark-heart-drug-trial-ticagrelor-plato-study-the-bmj 2024-12-12T01:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/8a77a25ab86a6f47/nec-announces-interim-results-from-phase-1-clinical-trial-of-necvax-neo1 2024-12-12T01:05:03+00:00 weekly 0.7 https://trial.medpath.com/news/de30d0c38ddb79f9/givlaari-effective-in-aip-patients-often-excluded-from-clinical-trials-porphyria-news 2024-12-12T00:00:03+00:00 weekly 0.7 https://trial.medpath.com/news/924505b3d65943e6/ladrx-plans-nda-submission-for-aldoxorubicin-under-505-b-2-pathway 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/065f3ad38d791044/boundless-bio-announces-pipeline-and-leadership-updates 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2246cdc03363132d/isatuximab-irfc-sarclisa-approved-for-multiple-myeloma-treatment 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1ea9a6b0b7e6a322/bayer-initiates-phase-i-study-with-sos1-inhibitor-for-advanced-kras-mutated-tumours 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d94daad7cb5d958a/ror1-a-promising-target-for-cancer-therapy 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/898c8adbe0891ec2/weight-loss-drugs-may-also-treat-addiction-alzheimers-and-heart-disease 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/38a0e497b5f2f4f1/how-revolutionary-ucsf-study-hopes-to-help-people-with-traumatic-brain-injuries 2024-12-11T23:58:21+00:00 weekly 0.7 https://trial.medpath.com/news/b3e40c8da36e8806/astrazeneca-sees-bright-future-for-registry-based-randomized-clinical-trials 2024-12-11T23:34:11+00:00 weekly 0.7 https://trial.medpath.com/news/e274d5d24befc949/pfizer-ceo-bourla-prevails-against-starboard-s-1b-activist-challenge 2024-12-11T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dccccf95833b4099/new-haven-biopharma-firm-veradermics-raises-75m-in-series-b-financing-round 2024-12-11T22:33:00+00:00 weekly 0.7 https://trial.medpath.com/news/805da052cc03c61d/fda-approves-neffy-new-nasal-spray-to-treat-severe-allergic-reactions-el-estoque 2024-12-11T22:28:51+00:00 weekly 0.7 https://trial.medpath.com/news/bd3477e177a73d8a/with-new-data-lilly-sets-pace-for-next-wave-of-breast-cancer-drugs-biopharma-dive 2024-12-11T22:27:04+00:00 weekly 0.7 https://trial.medpath.com/news/56251fb28677713b/study-uses-ai-to-cast-light-on-harmful-drug-drug-interactions-vumc-news 2024-12-11T21:52:41+00:00 weekly 0.7 https://trial.medpath.com/news/45f67daa2c299431/patritumab-deruxtecan-with-without-letrozole-shows-comparable-efficacy-in-hr-her2 2024-12-11T21:33:19+00:00 weekly 0.7 https://trial.medpath.com/news/0f3268ea7b1c8056/ash-2024-discussions-shine-spotlight-on-advances-in-haemophilia-treatments 2024-12-11T21:22:29+00:00 weekly 0.7 https://trial.medpath.com/news/6a224c074b35b05d/anaptysbio-pulls-out-of-eczema-drug-race-after-phase-ii-flop-firstword-pharma 2024-12-11T21:13:20+00:00 weekly 0.7 https://trial.medpath.com/news/7cc15c6fb29b2bb1/fempulse-receives-fda-ide-approval-for-the-pivotal-clinical-trial-of-its-wearable-morningstar 2024-12-11T20:44:40+00:00 weekly 0.7 https://trial.medpath.com/news/6bdad1f7cd260637/moderna-s-rsv-vaccines-run-into-safety-roadblock-biospace 2024-12-11T19:54:04+00:00 weekly 0.7 https://trial.medpath.com/news/18049e049cf32cb8/weight-loss-jabs-like-ozempic-may-reduce-effectiveness-of-breast-cancer-treatments-study-finds 2024-12-11T19:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/22dcfe39e8dd10bd/neoadjuvant-shr-a1811-demonstrates-efficacy-safety-in-her2-breast-cancer 2024-12-11T19:38:18+00:00 weekly 0.7 https://trial.medpath.com/news/1aa7883fdb671bf0/anne-sophie-michallet-md-phd-on-mrd-guided-vs-standard-combination-therapy-for 2024-12-11T19:21:40+00:00 weekly 0.7 https://trial.medpath.com/news/fcc23ecedd0d15b8/t-dxd-improves-pfs-irrespective-of-time-to-progression-type-of-endocrine-resistance-onclive 2024-12-11T19:13:48+00:00 weekly 0.7 https://trial.medpath.com/news/ff87779e21721d09/sound-pharma-gets-positive-results-from-meniere-s-disease-drug-clinical-trial 2024-12-11T19:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/27a69fc76e98ed45/ocugen-ceo-to-present-at-oppenheimer-movers-in-rare-disease-summit-quantisnow 2024-12-11T18:23:27+00:00 weekly 0.7 https://trial.medpath.com/news/298538929cf98fe6/cardiff-oncology-reports-promising-phase-2-trial-results-yahoo-finance 2024-12-11T18:20:20+00:00 weekly 0.7 https://trial.medpath.com/news/bdaf7598e4f49e05/covid-19-vaccine-efficacy-reduced-with-immunosuppressive-antiviral-hbv-drug-use 2024-12-11T18:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/e4655797ca2780ed/cardiff-oncology-announces-positive-colorectal-data-and-40m-stock-oversubscription 2024-12-11T17:51:20+00:00 weekly 0.7 https://trial.medpath.com/news/fcfb8510128ef3e6/ready-set-food-and-obviohealth-complete-recruitment-for-infant-food-allergy-study 2024-12-11T17:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/51e41e0337d7094e/anaptys-announces-phase-2b-trial-of-anb032-a-btla-agonist-did-not-meet-primary-or 2024-12-11T17:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/f4334885cb851400/enrollment-open-for-trial-testing-nkx019-cell-therapy-in-aav-anca-vasculitis-news 2024-12-11T17:16:38+00:00 weekly 0.7 https://trial.medpath.com/news/2ad1200bfb82e7fe/caredx-partners-with-tc-biopharm-to-support-achieve-clinical-trial-using-allocell-biospace 2024-12-11T17:11:49+00:00 weekly 0.7 https://trial.medpath.com/news/e04bb6c77d73e461/can-2409-improves-dfs-in-intermediate-high-risk-localized-prostate-cancer-onclive 2024-12-11T17:02:53+00:00 weekly 0.7 https://trial.medpath.com/news/19c1b4b1485b97a8/brain-sensing-car-t-cells-enhance-brain-tumor-therapy-inside-precision-medicine 2024-12-11T17:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/766b6b1ac316eae4/gc-biopharma-s-hunterase-icv-approved-in-russia-for-severe-hunter-syndrome 2024-12-11T17:01:11+00:00 weekly 0.7 https://trial.medpath.com/news/9f5593a4bc0a2294/memed-s-sepsis-test-receives-fda-breakthrough-device-status 2024-12-11T16:51:41+00:00 weekly 0.7 https://trial.medpath.com/news/4d64b8de49a6009f/clinical-trial-testing-sublingual-cladribine-planned-for-next-year 2024-12-11T16:46:38+00:00 weekly 0.7 https://trial.medpath.com/news/0bc36f7204dd0028/astria-therapeutics-announces-positive-final-results-from-target-enrollment-in-the-alpha 2024-12-11T16:45:38+00:00 weekly 0.7 https://trial.medpath.com/news/45909f90e129c838/q32-bio-battered-by-study-failure-of-immune-drug-biopharma-dive 2024-12-11T16:16:52+00:00 weekly 0.7 https://trial.medpath.com/news/75504dfbdd1db0b2/benevolentai-restructures-lilly-preps-15b-buyback-program-biopharma-dive 2024-12-11T16:16:51+00:00 weekly 0.7 https://trial.medpath.com/news/320e33911a2bf814/gnt-pharma-reports-significant-improvements-in-stroke-patients-treated-with-its-pr-newswire 2024-12-11T16:16:41+00:00 weekly 0.7 https://trial.medpath.com/news/54014b2d81c479bf/visible-trial-advances-diversity-in-psoriasis-research 2024-12-11T16:05:40+00:00 weekly 0.7 https://trial.medpath.com/news/49d5fc6aeb0eeb04/candel-therapeutics-stock-up-172-after-phase-iii-prostate-cancer-success 2024-12-11T15:50:08+00:00 weekly 0.7 https://trial.medpath.com/news/8f6868df1bfa810b/indian-scientists-develop-novel-gene-therapy-treatment-for-haemophilia 2024-12-11T15:41:00+00:00 weekly 0.7 https://trial.medpath.com/news/e4949b35b2c39205/updated-hep-b-vaccine-more-effective-for-people-with-hiv-newsroom 2024-12-11T15:37:31+00:00 weekly 0.7 https://trial.medpath.com/news/854eaa306b30d53a/lynparza-r-olaparib-demonstrated-clinically-meaningful-prolonged-survival-benefit-in 2024-12-11T15:36:42+00:00 weekly 0.7 https://trial.medpath.com/news/dd20fe7cb6ee7e61/rapidpulse-receives-fda-approval-to-begin-ide-study-in-ischemic-stroke-using-innovative 2024-12-11T15:36:04+00:00 weekly 0.7 https://trial.medpath.com/news/dc54f98ea3794b8c/lynparza-r-olaparib-demonstrated-clinically-meaningful-prolonged-survival-benefit-in 2024-12-11T15:27:39+00:00 weekly 0.7 https://trial.medpath.com/news/f41dbdaa870db9ed/gland-pharma-gets-us-fda-approval-for-vitamin-k-deficiency-injectable-cnbc-tv18 2024-12-11T15:24:06+00:00 weekly 0.7 https://trial.medpath.com/news/bd9acd2ec1c4b83c/neurosense-receives-positive-fda-feedback-on-phase-3-study-design-for-primec 2024-12-11T14:59:06+00:00 weekly 0.7 https://trial.medpath.com/news/117d07302b8e2cd4/ash-2024-inmind-study-results-position-monjuvi-as-a-promising-therapy-for-r-r-follicular-lymphoma 2024-12-11T14:56:25+00:00 weekly 0.7 https://trial.medpath.com/news/1104c92b34460e6a/ash24-leukemia-drug-sequencing-sickle-cell-questions-and-a-new-kind-of-car-t 2024-12-11T14:44:10+00:00 weekly 0.7 https://trial.medpath.com/news/5e80aa8ec321eb8a/nature-biotechnology-generative-chemistry-enables-insilico-to-develop-gut-restricted 2024-12-11T14:30:46+00:00 weekly 0.7 https://trial.medpath.com/news/cdec39d6ee0647d5/provectus-biopharmaceuticals-launches-visirose-provectus-s-globenewswire 2024-12-11T14:11:28+00:00 weekly 0.7 https://trial.medpath.com/news/dea8703c178da21b/gene-therapy-could-treat-alzheimer-s-disease-drug-discovery-news 2024-12-11T14:08:27+00:00 weekly 0.7 https://trial.medpath.com/news/4911434368217275/transposon-presents-results-from-successful-phase-2-als-ftd-clinical-trial-aftd 2024-12-11T14:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/e9d9aa140ca792f8/60-degrees-pharma-expands-promising-babesiosis-treatment-trial-to-brigham-women-s-hospital 2024-12-11T13:59:37+00:00 weekly 0.7 https://trial.medpath.com/news/d439f1acb00d5457/aprea-therapeutics-advances-novel-cancer-drug-trial-with-breakthrough-dosing-strategy 2024-12-11T13:37:58+00:00 weekly 0.7 https://trial.medpath.com/news/5932c4e176c8f833/moleculin-s-annamycin-shows-breakthrough-results-against-drug-resistant-leukemia-in-key-study 2024-12-11T13:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/0f43e718d57e33a0/satellos-announces-first-participant-with-duchenne-muscular-dystrophy-dosed-in-the-biospace 2024-12-11T12:50:04+00:00 weekly 0.7 https://trial.medpath.com/news/c03f1e159bb77e48/adams-clinical-announces-expansion-into-inpatient-psychiatry-and-schizophrenia-morningstar 2024-12-11T12:48:07+00:00 weekly 0.7 https://trial.medpath.com/news/9bb11622f05ff738/j-j-legend-shrug-off-carvykti-s-challengers-with-new-phase-iii-data-biospace 2024-12-11T12:46:56+00:00 weekly 0.7 https://trial.medpath.com/news/73e56eb65a60bcd9/reunion-neuroscience-presented-re104-phase-1-data-at-the-globenewswire 2024-12-11T12:44:27+00:00 weekly 0.7 https://trial.medpath.com/news/fc40eab1dc8ded29/review-confirms-clinical-safety-of-sandoz-denosumab-biosimilar-vs-originator 2024-12-11T12:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/36b8a718332fe33d/pharming-announces-positive-topline-data-in-pediatric-clinical-trial-of-leniolisib 2024-12-11T12:02:52+00:00 weekly 0.7 https://trial.medpath.com/news/8681e891b4860180/daiichi-sankyo-doses-first-subject-in-phase-iii-aml-therapy-trial 2024-12-11T11:57:47+00:00 weekly 0.7 https://trial.medpath.com/news/5babcc0ab72fbbaf/seastar-medical-projects-multibillion-dollar-market-globenewswire 2024-12-11T11:56:35+00:00 weekly 0.7 https://trial.medpath.com/news/03571a1a0011f393/fcrn-inhibitor-market-size-target-population-competitive-globenewswire 2024-12-11T11:27:02+00:00 weekly 0.7 https://trial.medpath.com/news/c20abd439a10ff44/immunotech-biopharm-ltd-announces-car-t-19-injection-receives-breakthrough-therapy 2024-12-11T11:20:33+00:00 weekly 0.7 https://trial.medpath.com/news/e9564e1da3db3c15/women-with-cancer-can-safely-use-rogaine-to-curb-hair-loss 2024-12-11T11:12:50+00:00 weekly 0.7 https://trial.medpath.com/news/ecef081da8e31638/removing-storing-patient-s-blood-before-liver-surgery-helps-avoid-transfusions 2024-12-11T11:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/e82b8abb2ea01b43/repare-therapeutics-to-host-webcast-to-report-data-from-the-lunresertib-and-camonsertib 2024-12-11T11:04:41+00:00 weekly 0.7 https://trial.medpath.com/news/926515abe375bb73/hunt-for-next-obesity-breakthrough-sends-biotech-stock-soaring-health-tech-world 2024-12-11T11:01:32+00:00 weekly 0.7 https://trial.medpath.com/news/da2787049c29388a/microbot-medical-r-announces-fda-submission-for-the-commercialization-of-the-liberty 2024-12-11T10:53:37+00:00 weekly 0.7 https://trial.medpath.com/news/8fbb8f45215006ee/press-release-two-combination-vaccine-candidates-for-prevention-of-influenza-and-covid 2024-12-11T10:45:36+00:00 weekly 0.7 https://trial.medpath.com/news/63cd42841f28e5a4/ionctura-reaches-new-clinical-milestones-in-uveal-melanoma-pr-newswire 2024-12-11T10:43:44+00:00 weekly 0.7 https://trial.medpath.com/news/398850356b18890d/will-eli-lilly-s-blockbuster-obesity-drug-be-available-in-india-by-2025-business-today 2024-12-11T10:41:54+00:00 weekly 0.7 https://trial.medpath.com/news/a796436cc4f4b410/insilico-medicine-advances-with-generative-ai-in-drug-discovery 2024-12-11T09:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/e65f9c4910a38bc7/cyrus-biotechnology-advances-cyr212-for-chronic-autoimmune-diseases-with-improved-igg-depletion-profile 2024-12-11T09:07:32+00:00 weekly 0.7 https://trial.medpath.com/news/38fd85cc0f72fab8/fda-approves-liga-chem-bio-s-ind-for-novel-adc-cancer-therapy-komedidaskeom 2024-12-11T09:07:09+00:00 weekly 0.7 https://trial.medpath.com/news/b3a0b8f6869d832c/tasca-therapeutics-launches-with-52-million-series-a-financing-to-develop-small-biospace 2024-12-11T08:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/a109ed875ab736f7/noema-pharma-ag-extends-series-b-financing-european-biotechnology-magazine 2024-12-11T08:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/8131e60c640945ae/osf-partners-with-the-kevin-brown-strong-foundation-to-fight-glioblastoma-with-clinical-trials 2024-12-11T08:30:09+00:00 weekly 0.7 https://trial.medpath.com/news/916c46b790d53c56/strategic-dose-rounding-in-biologics-balancing-cost-savings-with-patient-safety 2024-12-11T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/14cfe1dadebf6b0a/gene-therapy-cost-barriers-us-healthcare-faces-20-4-billion-annual-spending-challenge 2024-12-11T07:13:18+00:00 weekly 0.7 https://trial.medpath.com/news/b2d133e5e3698f8b/most-scd-patients-given-lyfgenia-in-trials-stay-free-of-voes-new-data 2024-12-11T06:12:31+00:00 weekly 0.7 https://trial.medpath.com/news/569e3e4e347f1bd1/news-researchers-launch-clinical-trial-testing-stellenbosch-university 2024-12-11T06:09:19+00:00 weekly 0.7 https://trial.medpath.com/news/e4791faf9df8c538/survey-reveals-top-challenges-for-biotechs-in-early-phase-clinical-trials 2024-12-11T05:23:58+00:00 weekly 0.7 https://trial.medpath.com/news/a09955c35dee25b3/gbm-organoids-models-patient-response-to-car-t-cell-therapy-in-real-time 2024-12-11T05:01:40+00:00 weekly 0.7 https://trial.medpath.com/news/5027403fe415729a/new-biomarker-testing-protocol-could-shorten-antibiotic-treatment-for-sepsis-news-medical 2024-12-11T04:15:27+00:00 weekly 0.7 https://trial.medpath.com/news/20c295580eba43ab/dr-wang-on-ziftomenib-plus-intensive-induction-in-newly-diagnosed-mutated-aml 2024-12-11T03:48:24+00:00 weekly 0.7 https://trial.medpath.com/news/55b4e77655de50b2/novel-drug-fails-for-two-rare-seizure-disorders-medpage-today 2024-12-11T03:26:59+00:00 weekly 0.7 https://trial.medpath.com/news/db5bb0b29ebec0b7/pilatus-biosciences-inc-secures-fda-orphan-drug-designation-for-plt012-pr-newswire 2024-12-11T03:13:38+00:00 weekly 0.7 https://trial.medpath.com/news/2be35ce3fe3a26fc/a-continued-evolution-psychiatric-times 2024-12-11T03:01:26+00:00 weekly 0.7 https://trial.medpath.com/news/a536d0087779d60c/november-s-fda-approvals-include-autolus-cd19-car-t-biocentury 2024-12-11T02:17:17+00:00 weekly 0.7 https://trial.medpath.com/news/7aba47555d2a7b93/glofitamab-plus-polatuzumab-shows-durable-results-in-r-r-lbcl-targeted-oncology 2024-12-11T01:32:52+00:00 weekly 0.7 https://trial.medpath.com/news/24064607c42e4b2e/bringing-it-all-back-home-reshaping-ophthalmology-s-clinic-with-home-oct-hcplive 2024-12-11T01:06:26+00:00 weekly 0.7 https://trial.medpath.com/news/3fa4e2c10fd49db3/kira-pharmaceuticals-presents-updated-data-of-phase-2-study-of-kp104-in-paroxysmal 2024-12-11T01:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/f5db9926846d02e3/tyra-biosciences-stock-target-adjusted-following-clinical-data-review 2024-12-11T00:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/3bd98095024a0eb9/visirose-unveils-breakthrough-therapy-for-eye-infections-mirage-news 2024-12-11T00:44:58+00:00 weekly 0.7 https://trial.medpath.com/news/de4437d0b293d147/psyence-biomed-executes-binding-agreements-with-optimi-health-corp-stock-titan 2024-12-11T00:39:10+00:00 weekly 0.7 https://trial.medpath.com/news/126a7f95a833b6ca/iv-form-of-nac-receives-fda-snda-to-prevent-lessen-liver-injury-after-ingesting-toxic 2024-12-11T00:23:58+00:00 weekly 0.7 https://trial.medpath.com/news/bae7854c0f9494d6/alternating-modified-capox-capiri-plus-bevacizumab-in-untreated-unresectable-metastatic 2024-12-11T00:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/62577de1f4880167/prospective-clinical-utility-study-of-lucid-diagnostics-esoguard-r-esophageal-dna-test-accepted-for-peer-reviewed-publication 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cfca3f95efa728c8/the-future-of-factor-xi-inhibitors-in-atrial-fibrillation-treatment 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9ab303f98274aed7/accent-therapeutics-doses-first-patient-in-phase-1-2-trial-of-atx-559-and-announces-cso-transition 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9d18fd3637b12d56/new-clinical-trial-of-etns-for-pediatric-adhd-to-commence-in-denmark 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fd93eba5c32ca2a3/point72-asset-management-l-p-has-1-23-million-position-in-acelyrin-inc-nasdaq-slrn 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dfcf93a50750d97c/prophylactic-tocilizumab-may-enhance-access-to-bispecific-therapies-for-multiple-myeloma 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d3dd1ebf2be9bacc/novotech-selected-for-new-covid-19-clinical-trial-in-asia-pacific 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dca4d2eb4143e1fd/protaryx-medical-completes-first-in-human-trial-of-transseptal-puncture-device 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7cbdaff2b7d1a6a0/acelyrin-price-target-lowered-to-13-from-15-at-wells-fargo-tipranks-com 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/432014f1d9b4ff47/teclistamab-shows-promising-results-in-chinese-patients-with-relapsed-refractory-multiple-myeloma 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4f61a634f6690abd/belhaven-biopharma-to-present-nasdepi-r-data-at-ddl-2024 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/43b23b4f8ec86183/ideaya-announces-first-patient-in-for-phase-1-clinical-trial-evaluating-ide161-in-pr-newswire 2024-12-10T23:01:04+00:00 weekly 0.7 https://trial.medpath.com/news/1e4e91fe3d543de1/mirum-pharmaceuticals-advances-in-liver-disease-treatments 2024-12-10T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7c2db75cf8ea0877/therapy-for-genetic-epilepsy-in-children-showing-promise-vumc-news 2024-12-10T22:52:50+00:00 weekly 0.7 https://trial.medpath.com/news/f951330143322225/positive-new-data-and-strong-recruitment-in-pancreatic-cancer-trial-biomelbourne-network 2024-12-10T22:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/0b4f025d42e9d6d7/ignite-biomedical-achieves-key-milestone-in-precision-medicine-with-successful-analytical 2024-12-10T22:09:27+00:00 weekly 0.7 https://trial.medpath.com/news/9e898484112059af/cellectar-biosciences-provides-strategic-update-on-clinical-development-pipeline 2024-12-10T22:03:59+00:00 weekly 0.7 https://trial.medpath.com/news/25ae341c08bdf835/acelyrin-inc-announces-topline-results-from-phase-2b-3-globenewswire 2024-12-10T21:46:29+00:00 weekly 0.7 https://trial.medpath.com/news/f086624aa68cd6b5/therapeutic-clinical-trial-eligibility-and-enrollment-among-women-with-breast-cancer 2024-12-10T21:12:13+00:00 weekly 0.7 https://trial.medpath.com/news/aaf034b9cbde8e26/moberg-pharma-reports-topline-data-in-the-north-american-phase-3-study-and-will-regain 2024-12-10T20:49:34+00:00 weekly 0.7 https://trial.medpath.com/news/93d0b6d2f0305754/axi-cel-demonstrates-long-term-efficacy-in-relapsed-refractory-follicular-lymphoma-and-marginal-zone-lymphoma 2024-12-10T20:33:10+00:00 weekly 0.7 https://trial.medpath.com/news/27b79ed219ed988c/md-anderson-and-ammax-bio-announce-agreements-to-advance-development-of-amb-066 2024-12-10T20:18:39+00:00 weekly 0.7 https://trial.medpath.com/news/6fa9f4ab6094e136/nih-study-finds-tecovirimat-was-safe-but-did-not-improve-mpox-resolution-or-pain 2024-12-10T20:16:23+00:00 weekly 0.7 https://trial.medpath.com/news/bb152d670406c694/hope-for-parkinson-s-disease-symptoms-is-found-in-late-stage-drug-study-fortune 2024-12-10T20:13:29+00:00 weekly 0.7 https://trial.medpath.com/news/b280432e5d5b5656/pirtobrutinib-triplet-improves-mrd-outcomes-in-cll-cancer-network 2024-12-10T20:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/71702acb89771684/astria-therapeutics-announces-fda-clearance-of-ind-application-for-star-0310-a-biospace 2024-12-10T19:41:48+00:00 weekly 0.7 https://trial.medpath.com/news/a915f6be419df5d2/revolutionary-cancer-drug-could-remove-side-effects-from-radiation-treatments-study-finds 2024-12-10T19:40:38+00:00 weekly 0.7 https://trial.medpath.com/news/8cbd3e152278159a/lisata-therapeutics-announces-completion-of-enrollment-in-the-cendifox-trial 2024-12-10T19:39:48+00:00 weekly 0.7 https://trial.medpath.com/news/1af30cb14bdd2e84/harnessing-ai-for-smarter-health-policy-research-school-of-public-health-brown-university 2024-12-10T19:19:49+00:00 weekly 0.7 https://trial.medpath.com/news/8365a9beffd3776b/cervomed-announces-topline-data-from-rewind-lb-phase-2b-clinical-trial-in-patients-with 2024-12-10T19:12:07+00:00 weekly 0.7 https://trial.medpath.com/news/c3e64fe2513a966e/ash-2024-regeneron-s-ordspono-faces-challenges-but-positive-results-signal-hope 2024-12-10T19:11:41+00:00 weekly 0.7 https://trial.medpath.com/news/a6730ebd92c00d08/eli-lilly-to-test-obesity-medications-as-treatments-for-alcohol-and-drug-addiction-stat-news 2024-12-10T19:05:14+00:00 weekly 0.7 https://trial.medpath.com/news/9c823f902bc497c4/alveron-pharma-closes-eur5-million-seed-extension-financing-to-accelerate-breakthrough-ich-therapy 2024-12-10T18:50:41+00:00 weekly 0.7 https://trial.medpath.com/news/d0a2af2120b24d2b/geron-announces-new-imerge-analyses-presented-at-ash-suggesting-clinical-activity-of 2024-12-10T18:41:35+00:00 weekly 0.7 https://trial.medpath.com/news/4d642190b76a4765/arvinas-pfizer-partner-cancer-drug-trial-shows-63-clinical-benefit-in-breast-cancer-patients 2024-12-10T18:31:47+00:00 weekly 0.7 https://trial.medpath.com/news/61e2e36c87ec3fb9/btk-degrader-bgb-16673-shows-promise-in-r-r-wm-and-cll-sll-cancer-network 2024-12-10T18:28:23+00:00 weekly 0.7 https://trial.medpath.com/news/1e805e2a450c3c9e/new-strategy-for-vivoryon-as-second-failed-alzheimer-s-trial-shows-kidney-promise 2024-12-10T18:15:47+00:00 weekly 0.7 https://trial.medpath.com/news/018b6755fcf4ea1b/carvykti-significantly-boosts-survival-mrd-negativity-in-relapsed-multiple-myeloma 2024-12-10T17:26:52+00:00 weekly 0.7 https://trial.medpath.com/news/e19192236d462b52/merus-mrus-fda-approval-and-speculative-future-in-cancer-therapy-yahoo-finance 2024-12-10T17:13:40+00:00 weekly 0.7 https://trial.medpath.com/news/ada9ced077481572/ramose-phase-ii-trial-finds-promising-results-for-osimertinib-and-ramucirumab-in-non-small 2024-12-10T16:14:47+00:00 weekly 0.7 https://trial.medpath.com/news/440af89a361d4586/humanetics-secures-additional-funding-to-advance-development-of-its-drug-to-prevent 2024-12-10T15:55:19+00:00 weekly 0.7 https://trial.medpath.com/news/b73b8406bb209859/pafolacianine-shows-no-serious-adverse-effects-in-lung-cancer-surgery 2024-12-10T15:26:04+00:00 weekly 0.7 https://trial.medpath.com/news/af1e9d4c64262d5d/uk-clinical-trials-performance-improves-but-remains-in-intensive-care 2024-12-10T15:09:49+00:00 weekly 0.7 https://trial.medpath.com/news/928337b736305627/why-is-cancer-focused-chimerix-stock-trading-higher-on-tuesday-yahoo-finance 2024-12-10T14:50:08+00:00 weekly 0.7 https://trial.medpath.com/news/361d740c6c6c07f4/the-start-center-for-cancer-research-expands-its-capabilities-to-support-early-phase 2024-12-10T14:44:29+00:00 weekly 0.7 https://trial.medpath.com/news/563db7e90458ab35/genmab-delivers-promising-data-from-cancer-drug-in-two-new-clinical-trials-medwatch 2024-12-10T14:25:38+00:00 weekly 0.7 https://trial.medpath.com/news/5a469fc4268d0e21/uniqure-gets-fda-ok-to-seek-accelerated-approval-stat-news 2024-12-10T14:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/b97936eb13b4f73b/atossa-therapeutics-to-present-pharmacokinetic-and-globenewswire 2024-12-10T14:10:43+00:00 weekly 0.7 https://trial.medpath.com/news/fd952a7e2dc82a4e/theradaptive-obtains-fda-ide-approval-to-study-osteoadapttm-sp-in-additional-spinal 2024-12-10T14:04:16+00:00 weekly 0.7 https://trial.medpath.com/news/94c2413c7be14bc9/thiogenesis-announces-presentation-on-umdf-webcast-featuring-clinical-trials-in 2024-12-10T14:03:56+00:00 weekly 0.7 https://trial.medpath.com/news/3092a559870a2436/curis-reports-promising-aml-study-results-by-investing-com 2024-12-10T13:46:13+00:00 weekly 0.7 https://trial.medpath.com/news/170fd66afa61d751/sirus-therapeutics-announces-positive-signals-from-phase-i-sirna-trial 2024-12-10T13:43:46+00:00 weekly 0.7 https://trial.medpath.com/news/7c5689190cbee10a/heart-specialists-praise-health-canada-approval-of-weight-loss-drug-wegovy-cp24 2024-12-10T13:41:18+00:00 weekly 0.7 https://trial.medpath.com/news/3b1b831350042389/sellas-life-sciences-triggers-interim-analysis-in-phase-3-regal-trial-of-gps-in-acute 2024-12-10T13:39:09+00:00 weekly 0.7 https://trial.medpath.com/news/3555647aa4b779d2/fda-opens-accelerated-approval-path-for-clene-s-breakthrough-als-treatment-after-78 2024-12-10T13:32:28+00:00 weekly 0.7 https://trial.medpath.com/news/2ae459b7bfc83343/curocell-s-car-t-therapy-picked-as-2nd-drug-for-expediated-approval-and-market-launch 2024-12-10T13:24:10+00:00 weekly 0.7 https://trial.medpath.com/news/2ce14bcaec4acbaa/global-biosimilars-market-set-to-triple-to-114-billion-by-2031-driven-by-patent-expirations-and-cost-advantages 2024-12-10T13:23:20+00:00 weekly 0.7 https://trial.medpath.com/news/fde85e7a549f32fe/sutro-biopharma-announces-selected-dose-for-luvelta-and-globenewswire 2024-12-10T13:11:34+00:00 weekly 0.7 https://trial.medpath.com/news/8afd0531583eccf4/renovorx-ceo-to-host-investor-fireside-chat-on-tuesday-december-17th-at-4-30-p-m-et 2024-12-10T13:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/7adfe13d861eddb2/onkure-announces-encouraging-preliminary-safety-and-pharmacokinetic-data-from-pikture-01-trial-of-oki-219 2024-12-10T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b65ca5b38d8870d2/quantum-biopharma-progresses-with-drug-trial-dosing-investing-com 2024-12-10T12:46:43+00:00 weekly 0.7 https://trial.medpath.com/news/2fc04e0f12f18f6f/lyell-immunopharma-announces-promising-initial-clinical-data-for-impt-314-in-treatment 2024-12-10T12:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/450f65d29be48959/uniqure-announces-alignment-with-fda-on-key-elements-of-accelerated-approval-pathway 2024-12-10T12:13:30+00:00 weekly 0.7 https://trial.medpath.com/news/d122c19882857569/scilex-forms-major-joint-venture-to-develop-novel-obesity-alzheimer-s-drug-after 2024-12-10T12:06:36+00:00 weekly 0.7 https://trial.medpath.com/news/79776650f3603ce3/merakris-therapeutics-announces-open-enrollment-for-phase-ii-clinical-trial-of-financial-post 2024-12-10T11:34:24+00:00 weekly 0.7 https://trial.medpath.com/news/34cc8e9186c718e8/glp-1-meds-may-lower-clot-risk-in-people-with-diabetes 2024-12-10T11:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/9e9e26f563dd8293/iaso-bio-s-car-t-therapy-shows-sustained-efficacy-in-multiple-myeloma-patients-with-renal-impairment 2024-12-10T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/af8e175e0fa03ce9/hvivo-plc-aim-hvo-ps11-5m-rsv-contract-and-notice-of-trading-update-share-talk 2024-12-10T09:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/ab0f5596f003a3db/olverembatinib-shows-promise-as-second-line-therapy-for-non-t315i-mutant-cp-cml 2024-12-10T08:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/6e8cd3bea239e535/ixico-lands-ps500k-phase-ii-huntington-s-contract-aim-ixi-otc-phyof-proactive-investors 2024-12-10T08:12:20+00:00 weekly 0.7 https://trial.medpath.com/news/942afa978ae4242d/santhera-receives-positive-recommendation-from-nice-for-agamree-r-vamorolone-as 2024-12-10T06:11:28+00:00 weekly 0.7 https://trial.medpath.com/news/bdaace4156fcc073/abbvie-s-tavapadon-shows-promise-in-phase-3-parkinson-s-disease-trial 2024-12-10T06:06:25+00:00 weekly 0.7 https://trial.medpath.com/news/7dfe95ebfcc215e1/new-and-updated-data-for-roche-s-fixed-duration-columvi-and-globenewswire 2024-12-10T06:02:08+00:00 weekly 0.7 https://trial.medpath.com/news/9ea593c952612329/experts-challenge-os-as-gold-standard-endpoint-in-cancer-drug-trials-pfs-gains-clinical-relevance 2024-12-10T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/98de1257c003e19a/comprehensive-management-guidelines-released-for-talquetamab-treatment-in-multiple-myeloma-patients 2024-12-10T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e62bddbed4c119f5/eye-disease-focused-kodiak-sciences-is-a-promising-turnaround-story-for-2025-benzinga 2024-12-10T05:36:22+00:00 weekly 0.7 https://trial.medpath.com/news/c9d4d5988836b44c/fda-approved-vowst-offers-novel-treatment-approach-for-recurrent-c-difficile-infections 2024-12-10T05:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/54860724a4ae054f/immune-onc-therapeutics-presents-updated-data-from-phase-1b-study-of-io-202-biospace 2024-12-10T05:02:14+00:00 weekly 0.7 https://trial.medpath.com/news/261036fcdfcac0c7/lyell-presents-positive-initial-clinical-data-from-the-phase-1-2-clinical-trial-of-impt-314-for 2024-12-10T05:02:14+00:00 weekly 0.7 https://trial.medpath.com/news/4a0b4a9dac77929c/glenmark-s-blood-cancer-drug-isb-2001-shows-83-response-rate-in-phase-1-multiple-myeloma-trial 2024-12-10T04:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/1f69cea77c0d6a84/immutep-initiates-phase-iii-trial-for-lung-cancer-markets-insider 2024-12-10T03:49:41+00:00 weekly 0.7 https://trial.medpath.com/news/f93e7dfe9fa50f6d/pediatric-cancer-clinical-trial-research-should-include-social-determinants-of-health 2024-12-10T02:50:02+00:00 weekly 0.7 https://trial.medpath.com/news/515e82d35facf307/ghana-becomes-first-river-blindness-endemic-country-to-approve-moxidectin-biomelbourne-network 2024-12-10T02:39:40+00:00 weekly 0.7 https://trial.medpath.com/news/d215c37e98cd68fa/zealand-pharma-announces-first-participant-enrolled-in-phase-2b-zupreme-1-trial-of-petrelintide-in-people-with-overweight-or-obesity 2024-12-10T02:12:56+00:00 weekly 0.7 https://trial.medpath.com/news/6afd93b696af2898/beigene-s-brukinsa-shows-breakthrough-71-risk-reduction-in-5-year-cll-study-at-ash 2024-12-10T01:31:17+00:00 weekly 0.7 https://trial.medpath.com/news/3cb4ea9dfee1a5ca/comprehensive-treatment-options-expand-for-non-familial-hypercholesterolemia-management 2024-12-10T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/80ec2ac4074c22f6/new-white-paper-highlights-critical-success-factors-for-modern-pharmaceutical-product-launches 2024-12-10T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8de7ac8c2ce06293/kites-yescarta-only-car-t-cell-therapy-to-show-durable-response-and-long-gilead-sciences 2024-12-10T00:34:16+00:00 weekly 0.7 https://trial.medpath.com/news/4d90189076f73d45/breakthrough-gene-therapy-offers-new-hope-to-child-with-muscular-dystrophy-the-tennessean 2024-12-10T00:18:40+00:00 weekly 0.7 https://trial.medpath.com/news/d12fc49493b9a028/positive-phase-3-trial-results-for-rilzabrutinib-support-buy-rating 2024-12-10T00:07:00+00:00 weekly 0.7 https://trial.medpath.com/news/28106ac464dd06b2/correcting-and-replacing-maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b80a965c6c1a66b3/tempus-announces-four-abstracts-accepted-for-presentation-at-the-2024-san-antonio-breast-cancer-symposium 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1530a5ecebe8b3bf/year-in-review-chronic-lymphocytic-leukemia 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/61c54d478e906a21/syntara-announces-positive-interim-data-in-phase-2-study-of-snt-5505-in-myelofibrosis 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cf9bad26a7033ba8/what-s-going-on-with-recursion-pharmaceuticals-stock 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8e2560a901a9f55a/major-milestone-for-uq-spin-out-s-promising-mnd-drug 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f98de0122b94afa4/tourmaline-bio-highlights-cardiovascular-inflammation-focus-and-announces-key-clinical-and-strategic-updates-at-investor-day 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a5ecccbbae83a2c4/with-promising-early-data-in-triple-negative-breast-cancer-a-new-bispecific-heats-up 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f3ee420a82fcf843/maia-biotechnology-secures-950k-private-placement-to-advance-thio-clinical-trials 2024-12-09T23:06:41+00:00 weekly 0.7 https://trial.medpath.com/news/804c81ce715587a2/regeneron-s-odronextamab-shows-remarkable-100-response-rate-in-lymphoma 2024-12-09T22:56:01+00:00 weekly 0.7 https://trial.medpath.com/news/9aec5c9452d37d0c/longest-follow-up-data-reported-for-kites-tecartus-car-t-cell-therapy-at-ash-2024 2024-12-09T22:47:26+00:00 weekly 0.7 https://trial.medpath.com/news/2e583b0c0f2aadc7/ash-2024-astrazeneca-set-to-take-a-bite-out-of-follicular-lymphoma-market 2024-12-09T22:40:19+00:00 weekly 0.7 https://trial.medpath.com/news/c0d961adae4da38a/spotlight-glow-trials-lead-to-fda-approval-of-zolbetuximab-clzb-with-chemotherapy 2024-12-09T22:15:51+00:00 weekly 0.7 https://trial.medpath.com/news/cc37e15ec24d9ed3/fda-approves-rezdiffra-first-fatty-liver-disease-drug-explained-woman-s-world 2024-12-09T21:49:37+00:00 weekly 0.7 https://trial.medpath.com/news/8816468840eadf45/sellas-stock-announces-positive-data-from-phase-2-trial-of-sls009-rttnews 2024-12-09T21:36:35+00:00 weekly 0.7 https://trial.medpath.com/news/fad765dcf42fe686/theratechnologies-initial-efficacy-data-from-ovarian-cancer-drug-trial-shows-encouraging-results 2024-12-09T21:36:16+00:00 weekly 0.7 https://trial.medpath.com/news/e25969f838236418/krystal-biotech-provides-update-on-ema-s-ongoing-regulatory-review-of-b-vec-for 2024-12-09T21:20:32+00:00 weekly 0.7 https://trial.medpath.com/news/3b807bc4d6211699/protagonist-reports-final-results-from-rusfertide-phase-2-revive-study-showing-durable 2024-12-09T21:19:20+00:00 weekly 0.7 https://trial.medpath.com/news/f789377b131ddf10/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-globenewswire 2024-12-09T21:10:47+00:00 weekly 0.7 https://trial.medpath.com/news/7fc43ac73c5c9961/fda-approves-acetadote-r-snda-stock-titan 2024-12-09T21:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/efca51a7b1f252da/survey-titrating-trofinetide-improves-tolerability-among-rett-syndrome-patients 2024-12-09T20:58:32+00:00 weekly 0.7 https://trial.medpath.com/news/9b8e25555a6fef72/new-drug-review-donanemab-azbt-approved-for-early-symptomatic-alzheimer-disease 2024-12-09T20:54:29+00:00 weekly 0.7 https://trial.medpath.com/news/b31e541994100e43/venetoclax-cladribine-improves-response-rates-in-aml-mds-cohorts-cancer-network 2024-12-09T20:39:11+00:00 weekly 0.7 https://trial.medpath.com/news/69f82a5197bbd718/insights-on-ucb-s-commitment-to-advancing-rare-epilepsy-care-neurologylive 2024-12-09T20:16:43+00:00 weekly 0.7 https://trial.medpath.com/news/ae2724ab0da81ca9/beacon-therapeutics-announces-positive-3-month-data-from-phase-2-dawn-trial-of-agtc 2024-12-09T20:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/60760582ff2047d2/secura-bio-presented-new-data-from-its-phase-2-primo-trial-of-copiktra-r-duvelisib-in 2024-12-09T20:07:50+00:00 weekly 0.7 https://trial.medpath.com/news/11db4f60795b7dc3/corbus-pharma-launches-phase-1-trial-for-novel-cancer-immunotherapy-crb-601 2024-12-09T19:57:35+00:00 weekly 0.7 https://trial.medpath.com/news/6509661b5a38105e/affimed-reports-promising-phase-1-efficacy-and-safety-data-for-afm28-in-relapsed-refractory-acute-myeloid-leukemia 2024-12-09T19:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/dd5c6c56969a61ec/first-patient-enrolled-in-inspiremd-s-cguardians-ii-pivotal-study-vascular-news 2024-12-09T19:28:58+00:00 weekly 0.7 https://trial.medpath.com/news/13030c319b0ee2b2/icer-potential-new-pain-medication-offers-small-savings-managed-healthcare-executive 2024-12-09T19:13:08+00:00 weekly 0.7 https://trial.medpath.com/news/91e4f58ae70e5e3f/deferasirox-achieves-transfusion-independence-in-mds-anemia-targeted-oncology 2024-12-09T19:04:09+00:00 weekly 0.7 https://trial.medpath.com/news/88c2250d02fdb4c3/carta-healthcare-to-power-oncology-research-and-clinical-trials-with-acquisition-pr-newswire 2024-12-09T19:01:35+00:00 weekly 0.7 https://trial.medpath.com/news/e9947a5484fb4627/fda-approves-new-cancer-treatments 2024-12-09T18:56:44+00:00 weekly 0.7 https://trial.medpath.com/news/26413862bc0c3378/adding-chemoradiation-in-perioperative-gastric-cancer-treatment-improves-pathologic 2024-12-09T18:47:57+00:00 weekly 0.7 https://trial.medpath.com/news/e88ed773e62490db/endo-receives-u-s-fda-approval-of-manufacturing-facility-in-indore-india 2024-12-09T18:20:58+00:00 weekly 0.7 https://trial.medpath.com/news/9c19d6a61b99364c/adenosine-antagonists-clinical-trial-pipeline-analysis-10-globenewswire 2024-12-09T18:05:53+00:00 weekly 0.7 https://trial.medpath.com/news/4010b30c143136be/eu-decision-time-for-orphans-acoramidis-garadacimab-imetelstat-plus-10-other-products 2024-12-09T17:23:33+00:00 weekly 0.7 https://trial.medpath.com/news/71e1228cfbaff45c/two-data-analyses-from-clinical-trials-show-epcoritamab-duobody-r-cd3xcd20 2024-12-09T17:07:53+00:00 weekly 0.7 https://trial.medpath.com/news/ba38a3dec582459c/tandem-non-cryopreserved-car-t-exhibits-favorable-activity-in-advanced-dlbcl-healio 2024-12-09T16:55:25+00:00 weekly 0.7 https://trial.medpath.com/news/75568e7e36abaa96/filling-out-the-roadmap-for-faster-drug-approvals-inventum 2024-12-09T16:43:28+00:00 weekly 0.7 https://trial.medpath.com/news/274b3e7b133221d6/simple-hysterectomy-not-inferior-to-radical-hysterectomy-for-cervical-cancer-treatment 2024-12-09T16:25:20+00:00 weekly 0.7 https://trial.medpath.com/news/506e95c2b01f4390/four-therapies-that-may-treat-kennedy-s-disease-brain-and-life-magazine 2024-12-09T16:24:03+00:00 weekly 0.7 https://trial.medpath.com/news/7b75e7e5bfc28e2f/fda-grants-ind-approval-to-base-therapeutics-base-edited-nk-cell-therapy-powered-by 2024-12-09T16:14:59+00:00 weekly 0.7 https://trial.medpath.com/news/c454b7e68500edb5/efficacy-and-safety-of-lenvatinib-plus-gefitinib-in-lenvatinib-resistant-hepatocellular-carcinomas 2024-12-09T15:43:23+00:00 weekly 0.7 https://trial.medpath.com/news/fd7e02819a847f96/interim-update-from-vico-therapeutics-on-their-cag-targeting-drug-vo659-hdbuzz 2024-12-09T15:41:17+00:00 weekly 0.7 https://trial.medpath.com/news/66e9a01ba5b3057c/high-fiber-diets-may-reduce-risk-of-gvhd-after-bone-marrow-stem-cell-transplants 2024-12-09T15:40:57+00:00 weekly 0.7 https://trial.medpath.com/news/101650bd973175cf/stereotaxis-wins-approval-in-china-for-magnetic-ablation-catheter-massdevice 2024-12-09T15:35:57+00:00 weekly 0.7 https://trial.medpath.com/news/9a505e0b50a42c00/tiakis-biotech-ag-reports-clinical-phase-ib-ii-trial-globenewswire 2024-12-09T15:01:43+00:00 weekly 0.7 https://trial.medpath.com/news/3cd5b5cc2f683005/modus-therapeutics-initiates-phase-ii-study-with-sevuparin-for-the-treatment-of-chronic-placera 2024-12-09T14:56:52+00:00 weekly 0.7 https://trial.medpath.com/news/84db35601e9e689c/rural-pharmacists-face-mounting-challenges-expert-highlights-critical-workforce-and-safety-concerns 2024-12-09T14:50:43+00:00 weekly 0.7 https://trial.medpath.com/news/7138dcc2d7b7b157/bionomics-publishes-the-positive-results-from-the-phase-2-attune-study-of-bnc210-biospace 2024-12-09T14:44:29+00:00 weekly 0.7 https://trial.medpath.com/news/9a379fc8f35afd25/first-subject-dosed-in-initial-cohort-of-phase-2b-clinical-study-of-cyanvac-s-intranasal-biospace 2024-12-09T14:43:54+00:00 weekly 0.7 https://trial.medpath.com/news/ed262804aec35e34/abbvie-drug-succeeds-in-another-parkinson-s-trial-stat-news 2024-12-09T14:25:06+00:00 weekly 0.7 https://trial.medpath.com/news/69adf18a62b1dc9a/gene-therapy-uptake-in-sickle-cell-stays-slow-despite-patient-interest-biopharma-dive 2024-12-09T14:20:34+00:00 weekly 0.7 https://trial.medpath.com/news/c5dccd3b5c34ff21/early-signs-of-efficacy-for-a-novel-drug-and-a-new-predictive-tool-to-guide-patient-care 2024-12-09T14:19:27+00:00 weekly 0.7 https://trial.medpath.com/news/29f28f52ca000bb8/relmada-halts-depression-drug-trials-shifts-focus-to-psilocybin-program-amid-review 2024-12-09T14:13:37+00:00 weekly 0.7 https://trial.medpath.com/news/9a16e8f287b9bbeb/woolsey-pharmaceuticals-reveals-breakthrough-findings-showing-spread-of-toxic-tdp-43 2024-12-09T14:02:49+00:00 weekly 0.7 https://trial.medpath.com/news/53d23553a11b644a/setpoint-medical-announces-filing-of-premarket-approval-pma-application-to-the-u-s 2024-12-09T13:55:37+00:00 weekly 0.7 https://trial.medpath.com/news/5b00e09a3a346672/novel-combination-studied-in-hpv16-positive-relapsed-or-metastatic-head-and-neck 2024-12-09T13:49:05+00:00 weekly 0.7 https://trial.medpath.com/news/0435de797370df52/vikram-narayan-md-on-cystectomy-outcomes-in-nadofaragene-treated-patients 2024-12-09T13:39:20+00:00 weekly 0.7 https://trial.medpath.com/news/bd416ddf415d15a3/serial-ctdna-to-understand-parpi-resistance-nature-reviews-urology 2024-12-09T13:38:22+00:00 weekly 0.7 https://trial.medpath.com/news/b2acc2c0df949a2b/new-uk-swiss-bilateral-funding-for-clinical-trials-to-open-in-2025-nihr 2024-12-09T13:31:38+00:00 weekly 0.7 https://trial.medpath.com/news/857818eb704adf7a/first-fda-approved-treatment-for-severe-frostbite-now-commercially-available-in-the-us 2024-12-09T13:25:23+00:00 weekly 0.7 https://trial.medpath.com/news/9c41355fb0c6a452/lomond-therapeutics-reports-results-from-ongoing-clinical-studies-of 2024-12-09T13:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/c12c3520a345ba77/crinetics-breakthrough-oral-acromegaly-drug-advances-as-fda-accepts-nda-for-stock-titan 2024-12-09T13:10:03+00:00 weekly 0.7 https://trial.medpath.com/news/c0d662050494c304/abbvie-s-parkinson-s-drug-tavapadon-shows-breakthrough-results-in-phase-3-trial-stock-titan 2024-12-09T13:09:37+00:00 weekly 0.7 https://trial.medpath.com/news/ffcd65cd430f3591/acurx-updates-phase-3-readiness-for-ibezapolstat-in-c-difficile-infection-based-on-recent 2024-12-09T13:04:30+00:00 weekly 0.7 https://trial.medpath.com/news/05e7dbc329fe6978/meiragtx-granted-fda-regenerative-medicine-advanced-therapy-globenewswire 2024-12-09T13:02:24+00:00 weekly 0.7 https://trial.medpath.com/news/7118ad9741834af8/artivion-granted-fda-humanitarian-device-exemption-for-the-amds-hybrid-prosthesis 2024-12-09T13:01:10+00:00 weekly 0.7 https://trial.medpath.com/news/a03dfe684f98c502/cantex-scores-third-fda-orphan-drug-win-for-breakthrough-breast-cancer-brain 2024-12-09T12:41:15+00:00 weekly 0.7 https://trial.medpath.com/news/d1dc8707099362da/adc-therapeutics-zynlonta-shows-breakthrough-97-response-rate-in-lymphoma 2024-12-09T12:31:46+00:00 weekly 0.7 https://trial.medpath.com/news/0366e742d8a71945/fda-grants-breakthrough-status-to-seres-infection-drug-investing-com 2024-12-09T12:29:51+00:00 weekly 0.7 https://trial.medpath.com/news/8835b437d87607ad/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-validation-of-pr-newswire 2024-12-09T12:18:57+00:00 weekly 0.7 https://trial.medpath.com/news/0faad7bcd26a011b/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-yahoo-finance 2024-12-09T12:15:03+00:00 weekly 0.7 https://trial.medpath.com/news/056bfc611b6c00e3/olema-pharma-s-novel-cancer-drug-op-3136-secures-fda-clearance-for-clinical-trials 2024-12-09T12:09:34+00:00 weekly 0.7 https://trial.medpath.com/news/a702d225ebb2ab91/nuvalent-appoints-grant-bogle-to-board-of-directors-citybiz 2024-12-09T12:00:50+00:00 weekly 0.7 https://trial.medpath.com/news/29a197ceaa7ae9fa/supriya-lifescience-gets-brazil-approval-for-mental-illness-drug-files-patent-for-heart 2024-12-09T11:48:58+00:00 weekly 0.7 https://trial.medpath.com/news/4f2d9c888a9f92f8/merck-announces-phase-3-keylynk-001-trial-met-primary-endpoint-of-progression-free 2024-12-09T11:47:15+00:00 weekly 0.7 https://trial.medpath.com/news/864328e45d584858/angiodynamics-receives-fda-clearance-for-the-nanoknife-r-system-for-prostate-tissue-ablation 2024-12-09T11:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/31d03b4d8f915e20/ideaya-biosciences-unveils-ide892-breakthrough-cancer-drug-candidate-with-promising 2024-12-09T11:09:50+00:00 weekly 0.7 https://trial.medpath.com/news/725f6ecb2a7320a3/cspc-pharmaceutical-s-breast-cancer-drug-gains-approval-tipranks-com 2024-12-09T10:23:07+00:00 weekly 0.7 https://trial.medpath.com/news/5be02858ad98bf45/rapport-therapeutics-presents-data-demonstrating-consistent-association-between-biospace 2024-12-09T10:17:11+00:00 weekly 0.7 https://trial.medpath.com/news/57bbf4f166fb8480/biomerieux-gains-fda-clearance-for-tropical-fever-test-markets-insider 2024-12-09T09:55:11+00:00 weekly 0.7 https://trial.medpath.com/news/1826f21fc2482c1f/cd40-targeted-therapies-clinical-trials-market-globenewswire 2024-12-09T09:49:40+00:00 weekly 0.7 https://trial.medpath.com/news/5b1dcad06cf6be21/liquid-biopsies-emerge-as-game-changer-in-precision-oncology-testing-expert-highlights-value-based-care-impact 2024-12-09T09:18:53+00:00 weekly 0.7 https://trial.medpath.com/news/108edc1cbe6e39cf/cytrill-bv-raises-eur85m-in-series-b-financing-european-biotechnology-magazine 2024-12-09T09:16:21+00:00 weekly 0.7 https://trial.medpath.com/news/61a287ef07e5ff40/hemogenyx-advances-clinical-trial-for-aml-treatment-tipranks-com 2024-12-09T07:59:26+00:00 weekly 0.7 https://trial.medpath.com/news/6a011614d70367c4/us-fda-accepts-gsk-s-submission-for-the-use-of-nucala-mepolizumab-in-copd-gsk 2024-12-09T07:03:41+00:00 weekly 0.7 https://trial.medpath.com/news/a6396d39816a605a/celltrion-gets-approval-of-omlyclo-in-canada-ked-global 2024-12-09T07:02:21+00:00 weekly 0.7 https://trial.medpath.com/news/244c3bd6840b9995/be-biopharma-unveils-become-9-trial-and-presents-on-versatile-b-cell-medicines-platform 2024-12-09T06:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/7c7cc0f0cb3e7b3f/aspc-congress-2024-ai-glp-1s-and-novel-imaging-reshape-cardiovascular-disease-prevention 2024-12-09T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3eecb4fe64f66d8d/clinical-trial-supply-chain-integration-critical-for-protocol-success-experts-emphasize 2024-12-09T05:50:38+00:00 weekly 0.7 https://trial.medpath.com/news/d81e49ff6d7cc207/paradigm-raises-16m-for-phase-iii-trial-of-knee-osteoarthritis-treatment-stockhead 2024-12-09T05:47:23+00:00 weekly 0.7 https://trial.medpath.com/news/592e35f59fec6373/ms-pharma-becomes-partner-for-the-commercialization-of-fyb202-ustekinumab-in-eqs-news 2024-12-09T05:33:07+00:00 weekly 0.7 https://trial.medpath.com/news/9db9397d278e6429/fda-action-alert-ionis-lexicon-astrazeneca-daiichi-sankyo-and-more-biospace 2024-12-09T05:22:09+00:00 weekly 0.7 https://trial.medpath.com/news/876cadb96aeecfaf/evidence-mounts-for-potential-of-glp-1s-in-alzheimer-s-disease-biospace 2024-12-09T05:04:49+00:00 weekly 0.7 https://trial.medpath.com/news/f5b5472143faeb5a/syneos-health-announces-webinar-on-healthcare-innovation-and-digital-transformation-trends-for-2025 2024-12-09T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b69f1c47ddbdae55/bridging-clinical-research-and-clinical-care-with-ai-aiding-pathologists-tool 2024-12-09T04:34:00+00:00 weekly 0.7 https://trial.medpath.com/news/1c3e7c9cd16f2845/china-medical-system-first-prescriptions-for-innovative-drug-lumeblue-r-issued-in-china 2024-12-09T04:07:50+00:00 weekly 0.7 https://trial.medpath.com/news/982a616976edd4e2/arcellx-s-multiple-myeloma-treatment-shows-breakthrough-97-response-rate-in-phase-2-trial 2024-12-09T04:04:45+00:00 weekly 0.7 https://trial.medpath.com/news/9f94cc620a2f5b78/alzheimer-s-disease-pipeline-drugs-2024-clinical-trials-ema-openpr-com 2024-12-09T03:49:07+00:00 weekly 0.7 https://trial.medpath.com/news/71904a3d412ae1cf/european-commission-approves-novo-holdings-16-5b-catalent-acquisition 2024-12-09T03:17:45+00:00 weekly 0.7 https://trial.medpath.com/news/f730c382066345b0/odronextamab-ash-presentations-underscore-impressive-potential-in-earlier-lines-of-treatment-and-additional-types-of-lymphoma 2024-12-09T03:12:43+00:00 weekly 0.7 https://trial.medpath.com/news/664b8b3b1ae7672e/sk-biopharmaceuticals-unveils-phase-3-cenobamate-results-in-northeast-asian-epilepsy 2024-12-09T02:59:42+00:00 weekly 0.7 https://trial.medpath.com/news/d03e4b4ff7a0873b/dr-foster-on-daratumumab-plus-lenalidomide-in-newly-diagnosed-myeloma-after-transplant 2024-12-09T02:57:45+00:00 weekly 0.7 https://trial.medpath.com/news/47bb18dd05e96b02/us-real-world-analysis-supports-clinical-benefit-of-tafasitamab-in-r-r-dlbcl-onclive 2024-12-09T02:41:36+00:00 weekly 0.7 https://trial.medpath.com/news/64097e3a5a27dee2/fs118-showcases-modest-efficacy-in-relapsed-refractory-dlbcl-onclive 2024-12-09T01:56:30+00:00 weekly 0.7 https://trial.medpath.com/news/6bceb9e9239f8239/puberty-blockers-can-a-drug-trial-solve-the-big-debate-bbc 2024-12-09T01:35:09+00:00 weekly 0.7 https://trial.medpath.com/news/044a3217b46a22fd/disc-medicine-s-myelofibrosis-drug-shows-breakthrough-results-in-phase-1b-trial-with-100 2024-12-09T01:14:36+00:00 weekly 0.7 https://trial.medpath.com/news/fd75b5f1caa83299/genomic-landscape-of-circulating-tumor-dna-in-her2-low-metastatic-breast-cancer-nature 2024-12-09T01:08:28+00:00 weekly 0.7 https://trial.medpath.com/news/611eb69068f29e5b/maintenance-teclistamab-yields-preliminary-activity-in-ndmm-cancer-network 2024-12-09T00:47:19+00:00 weekly 0.7 https://trial.medpath.com/news/b2e87be5b84d2de1/agios-phase-3-trial-breakthrough-mitapivat-shows-3x-better-results-for-thalassemia-treatment 2024-12-09T00:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/81976e3723837b66/pharma-s-memorable-moments-of-2024-c-en-american-chemical-society 2024-12-09T00:29:25+00:00 weekly 0.7 https://trial.medpath.com/news/019399194d4f709a/actinogen-medical-expands-alzheimer-s-drug-trial-to-us 2024-12-09T00:27:44+00:00 weekly 0.7 https://trial.medpath.com/news/166c822be2defbe5/innovent-presents-updated-data-from-innovative-anti-cldn18-2-adc-ibi343-phase-1 2024-12-09T00:15:03+00:00 weekly 0.7 https://trial.medpath.com/news/1620233002354845/key-fda-approvals-in-2024-c-en 2024-12-09T00:07:42+00:00 weekly 0.7 https://trial.medpath.com/news/617d88905b832942/promising-results-for-disitamab-vedotin-plus-toripalimab-in-locally-advanced-or-metastatic-urothelial-carcinoma 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8d44a71b77c28f6b/glp-1-agonists-market-2034-clinical-trials-ema-pdma-fda-approvals-target-population-companies-delveinsight 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bd25e5a6f5bd35b8/batten-disease-research-updates-with-dr-ineka-whiteman 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a1d7c975dbbcc548/aptose-clinical-data-featured-in-poster-presentation-at-the-2024-ash-annual-meeting-support-tuspetinib-triple-drug-therapy-for-newly-diagnosed-aml 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8a6a2084df46c255/endometriosis-research-faces-funding-hurdles-despite-affecting-10-of-women-globally 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bbb8ca0ff22474a8/iopofosine-i-131-shows-promising-results-in-previously-treated-waldenstrom-macroglobulinemia-patients 2024-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9d295da19bbf6c9a/anlotinib-plus-chemotherapy-as-a-first-line-treatment-for-gastrointestinal-cancer-patients-with 2024-12-08T23:35:10+00:00 weekly 0.7 https://trial.medpath.com/news/7ae5c33676659453/zilovertamab-vedotin-r-chp-elicits-high-complete-response-rate-in-dlbcl 2024-12-08T23:32:27+00:00 weekly 0.7 https://trial.medpath.com/news/231cd8fa47a9e4c0/molecular-partners-presents-clinical-data-supporting-its-ongoing-mp0533-study-quantisnow 2024-12-08T23:12:09+00:00 weekly 0.7 https://trial.medpath.com/news/6db69b930b1f9795/aes-poster-provides-safety-insights-to-antiseizure-medication-fenfluramine-neurologylive 2024-12-08T23:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/a158c09a0426b001/vertex-presents-positive-long-term-data-on-casgevytm-exagamglogene-autotemcel-at 2024-12-08T23:03:41+00:00 weekly 0.7 https://trial.medpath.com/news/b4d9345066f31680/dr-mauz-koerholz-on-the-role-of-pembrolizumab-in-younger-patients-with-low-risk 2024-12-08T23:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/a23092c743478bda/positive-efficacy-and-safety-outcomes-result-from-second-line-liso-cel-in-lbcl 2024-12-08T22:47:30+00:00 weekly 0.7 https://trial.medpath.com/news/478ce4ab7cfe14ce/navtemadlin-monotherapy-shows-improvements-in-hallmarks-of-r-r-myelofibrosis 2024-12-08T22:37:20+00:00 weekly 0.7 https://trial.medpath.com/news/10d1e149b91ff985/novel-ptsd-treatment-improved-symptom-severity-in-phase-iib-trial-medpage-today 2024-12-08T22:17:32+00:00 weekly 0.7 https://trial.medpath.com/news/244bbfd288e88464/preventing-vocs-in-people-with-sickle-cell-disease-with-exa-cel-gene-editing-therapy 2024-12-08T21:47:03+00:00 weekly 0.7 https://trial.medpath.com/news/8d298af1f36448e5/asciminib-continues-to-best-soc-tkis-as-secondary-end-points-of-asc4first-trial-are-met 2024-12-08T21:26:36+00:00 weekly 0.7 https://trial.medpath.com/news/d35ce602bb9b2687/brexu-cel-displays-comparable-efficacy-across-age-groups-in-relapsed-refractory-b-all 2024-12-08T21:26:34+00:00 weekly 0.7 https://trial.medpath.com/news/8569c87778dfd835/olverembatinib-may-be-effective-in-second-line-for-cp-cml-onclive 2024-12-08T21:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/0e7be3e0fb5657a1/beam-therapeutics-presents-new-non-human-primate-nhp-data-demonstrating-proof-of 2024-12-08T20:57:54+00:00 weekly 0.7 https://trial.medpath.com/news/051acf7221e87e0a/new-clinical-trial-hopes-to-find-gold-standard-for-staging-lobular-breast-cancer 2024-12-08T20:30:15+00:00 weekly 0.7 https://trial.medpath.com/news/e36eed33c53cbfac/merck-s-cancer-drug-achieves-100-complete-response-rate-in-phase-2-lymphoma-trial 2024-12-08T20:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/6e95683a240a1d19/dr-kaddoura-on-genomic-determinants-of-outcomes-in-igh-ccnd1-myeloma-treated-onclive 2024-12-08T20:10:48+00:00 weekly 0.7 https://trial.medpath.com/news/e470aa7d146878c0/astrazeneca-reports-positive-results-from-amplify-phase-3-trial-tipranks-com 2024-12-08T20:02:15+00:00 weekly 0.7 https://trial.medpath.com/news/7f976ababefeefdc/healy-center-for-als-presents-the-lalji-award-for-innovative-healing 2024-12-08T19:47:51+00:00 weekly 0.7 https://trial.medpath.com/news/cdfc71c3af3cfea9/conduct-phase-iii-clinical-study-on-resistant-hypertension-cdsco-panel-tells-sun 2024-12-08T18:22:17+00:00 weekly 0.7 https://trial.medpath.com/news/232b18d282144921/mitsubishi-tanabe-pharma-america-to-present-data-on-investigational-nd0612-at-the-2024 2024-12-08T17:58:22+00:00 weekly 0.7 https://trial.medpath.com/news/95038b15caa095d2/five-year-results-confirm-genentech-s-polivy-combination-therapy-as-new-standard-of 2024-12-08T17:53:45+00:00 weekly 0.7 https://trial.medpath.com/news/ba9da717795184b2/kite-presents-new-data-underscoring-curative-potential-of-yescarta-r-in-relapsed-quantisnow 2024-12-08T17:42:11+00:00 weekly 0.7 https://trial.medpath.com/news/03530f734316fe69/tecvayli-r-teclistamab-cqyv-demonstrates-potential-as-frontline-combination-therapy-for 2024-12-08T17:39:46+00:00 weekly 0.7 https://trial.medpath.com/news/13a76d6b131cbe5a/roswell-park-experts-report-insights-on-car-t-for-follicular-lymphoma-keynote-667 2024-12-08T17:33:15+00:00 weekly 0.7 https://trial.medpath.com/news/91493a7bd9397a0f/cogent-biosciences-announces-positive-updated-data-from-ongoing-phase-2-apex-trial 2024-12-08T17:12:10+00:00 weekly 0.7 https://trial.medpath.com/news/7daa966ea7510f31/antibody-shows-encouraging-results-for-treating-high-risk-follicular-lymphoma-and 2024-12-08T17:01:10+00:00 weekly 0.7 https://trial.medpath.com/news/3b0123f88781a680/darzalex-r-daratumumab-subcutaneous-formulation-shows-51-globenewswire 2024-12-08T16:33:08+00:00 weekly 0.7 https://trial.medpath.com/news/f12ac6d8cc8f5db7/multi-center-study-shows-education-level-income-impact-access-to-stem-cell-transplantation 2024-12-08T16:28:37+00:00 weekly 0.7 https://trial.medpath.com/news/876fdc5a36535dae/combining-bcl-2-and-btk-inhibitors-shows-promise-in-cll-dana-farber-cancer-institute 2024-12-08T16:17:47+00:00 weekly 0.7 https://trial.medpath.com/news/2a9f247a17caa913/fixed-duration-calquence-plus-venetoclax-demonstrated-superior-pfs-vs-standard-of-care 2024-12-08T16:06:17+00:00 weekly 0.7 https://trial.medpath.com/news/80c5f5fc23321aca/studies-highlight-progress-in-preventing-and-treating-blood-cancers-and-pre-cancerous-conditions 2024-12-08T16:04:54+00:00 weekly 0.7 https://trial.medpath.com/news/9fa93712f2d32540/lymphoma-immunotherapy-enhanced-by-enzyme-inhibitor-in-preclinical-model-prompting 2024-12-08T15:16:04+00:00 weekly 0.7 https://trial.medpath.com/news/0c476bd04e3a3e03/maxx-orthopedics-announces-fda-clearance-of-medial-congruent-insert-for-tka-system 2024-12-08T15:14:08+00:00 weekly 0.7 https://trial.medpath.com/news/293ce2d82f05ec13/dr-jurczak-on-the-efficacy-and-safety-of-nemtabrutinib-in-r-r-follicular-lymphoma 2024-12-08T15:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/a87355ee99e53d18/hydroxyurea-shows-clinical-benefit-in-hbsc-misses-the-mark-on-safety-hcplive 2024-12-08T14:31:59+00:00 weekly 0.7 https://trial.medpath.com/news/d07f0ae885752960/abbisko-cayman-reports-promising-cgvhd-drug-results-markets-insider 2024-12-08T14:31:53+00:00 weekly 0.7 https://trial.medpath.com/news/197549c575cee282/countdown-to-neo-brain-computer-interface-clinical-trial-in-china 2024-12-08T14:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/e58a9f786fd4f3e8/covid-19-vaccination-effective-in-preventing-long-covid-in-young-people 2024-12-08T14:10:06+00:00 weekly 0.7 https://trial.medpath.com/news/ba1a49e1816bf928/is-your-mind-ready-to-consider-investing-in-psychedelics-stocks 2024-12-08T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/42985a46992894a9/ppbt-stock-surges-150-on-superior-efficacy-of-pdac-combo-therapy 2024-12-08T11:55:36+00:00 weekly 0.7 https://trial.medpath.com/news/66acdb3c36bf2b8b/commonly-prescribed-drugs-increase-dementia-risk-study-finds-surrey-live 2024-12-08T11:14:17+00:00 weekly 0.7 https://trial.medpath.com/news/741b35ede3173fa5/siamak-daneshmand-md-on-safety-tolerability-data-from-sunrise-1-urology-times 2024-12-08T11:03:57+00:00 weekly 0.7 https://trial.medpath.com/news/d24e4d34a9c553f4/ash-expert-axi-cel-treatment-causes-decreased-incidence-severity-of-toxicities-in-large 2024-12-08T10:54:23+00:00 weekly 0.7 https://trial.medpath.com/news/fdf1d982fbd40694/regeneron-pharmaceuticals-releases-positive-phase-3-trial-data-for-poze-cemdi 2024-12-08T10:23:03+00:00 weekly 0.7 https://trial.medpath.com/news/1371b96099d13a12/ash-novo-s-etavopivat-for-sickle-cell-disease-cuts-voc-rates-in-half 2024-12-08T09:58:31+00:00 weekly 0.7 https://trial.medpath.com/news/59fe6f4b5b210041/biden-administration-s-access-model-offers-hope-for-cell-and-gene-therapies-forbes 2024-12-08T08:17:55+00:00 weekly 0.7 https://trial.medpath.com/news/ce042b2677fd8c7b/receiving-asct-after-first-cr-may-improve-certain-outcomes-in-aml 2024-12-08T07:23:08+00:00 weekly 0.7 https://trial.medpath.com/news/51dc724b294f03fb/sanofi-advances-a-drug-for-a-rare-platelet-destroying-disease-stat-news 2024-12-08T05:21:36+00:00 weekly 0.7 https://trial.medpath.com/news/290f372e8fb3679b/ketogenic-diet-and-b-hydroxybutyrate-may-enhance-car-t-cell-therapy-efficacy 2024-12-08T04:55:26+00:00 weekly 0.7 https://trial.medpath.com/news/93df0de655353d42/researchers-report-new-opportunities-to-improve-quality-of-life-for-people-with-pr-newswire 2024-12-08T04:31:56+00:00 weekly 0.7 https://trial.medpath.com/news/c22bd70ce54a9663/oral-revumenib-based-combo-produces-responses-in-r-r-aml-onclive 2024-12-08T03:14:48+00:00 weekly 0.7 https://trial.medpath.com/news/c1625243ca78b3da/scitech-development-welcomes-john-chapman-to-the-strategic-advisory-board-as-senior 2024-12-08T02:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/9635fe667390e971/promising-results-for-novel-triplet-therapy-in-high-risk-chronic-lymphocytic-leukemia 2024-12-08T01:51:07+00:00 weekly 0.7 https://trial.medpath.com/news/0d766f8dcf938cf6/program-targets-poverty-to-improve-childhood-cancer-treatment 2024-12-08T00:42:09+00:00 weekly 0.7 https://trial.medpath.com/news/4963d4404cf74628/investigational-epcoritamab-duobody-r-cd3xcd20-combination-therapy-shows-high 2024-12-08T00:39:32+00:00 weekly 0.7 https://trial.medpath.com/news/ae65a5d4927d96bb/industry-updates-from-floretina-icoor-2024-ophthalmology-times-europe 2024-12-08T00:26:22+00:00 weekly 0.7 https://trial.medpath.com/news/7d3550f5d25309f1/novel-combination-of-pozelimab-and-cemdisiran-poze-cemdi-achieved-greater-control 2024-12-08T00:06:29+00:00 weekly 0.7 https://trial.medpath.com/news/584434b8f9d2a22f/news-and-events-aviceda-therapeutics 2024-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3d9e4ec527a277a5/adaptive-biotechnologies-announces-new-data-at-the-66th-ash-globenewswire 2024-12-07T23:35:57+00:00 weekly 0.7 https://trial.medpath.com/news/739cf93894dece24/clinical-trials-uganda-makes-major-advances-new-vision-official 2024-12-07T23:34:19+00:00 weekly 0.7 https://trial.medpath.com/news/a2fbf70275d2a7af/galapagos-announces-encouraging-new-results-from-ongoing-phase-1-2-study-of-cd19 2024-12-07T23:20:40+00:00 weekly 0.7 https://trial.medpath.com/news/28cd87fc9f40aee3/tandem-cd20-cd19-car-zamto-cel-shows-promise-in-dlbcl-cgtlive-r 2024-12-07T21:18:49+00:00 weekly 0.7 https://trial.medpath.com/news/cf157c972d9ac927/blincyto-r-blinatumomab-added-to-chemotherapy-significantly-amgen 2024-12-07T21:11:08+00:00 weekly 0.7 https://trial.medpath.com/news/a460d890649828e8/rapcabtagene-autoleucel-shows-promise-for-dlbcl-in-updated-phase-2-data-cgtlive-r 2024-12-07T20:18:38+00:00 weekly 0.7 https://trial.medpath.com/news/c175b23969e2661a/uk-approves-pfizer-biontech-covid-19-vaccine-first-in-the-world-abs-cbn-news 2024-12-07T19:54:34+00:00 weekly 0.7 https://trial.medpath.com/news/fa650a62b941d675/commands-trial-shows-impact-of-luspatercept-on-rbc-transfusion-burden-in-lr-mds 2024-12-07T19:38:32+00:00 weekly 0.7 https://trial.medpath.com/news/ec24417aeab6e1af/reliev2-cm-study-launched-dose-finding-portion-of-anqur-underway-anavex-submits 2024-12-07T18:14:07+00:00 weekly 0.7 https://trial.medpath.com/news/45cf7766381eb148/sickle-cell-breakthrough-base-editing-success-mirage-news 2024-12-07T17:53:03+00:00 weekly 0.7 https://trial.medpath.com/news/503dcf10c8a0bfa7/updated-results-of-phase-3-allele-study-presented-at-66th-american-society-of-pr-newswire 2024-12-07T17:45:34+00:00 weekly 0.7 https://trial.medpath.com/news/262cf997fee9d35f/latest-advances-in-aml-treatment-highlighted-at-ash-2024-annual-meeting 2024-12-07T17:43:00+00:00 weekly 0.7 https://trial.medpath.com/news/fb8c8314a5b477a8/talazoparib-plus-enzalutamide-versus-olaparib-plus-abiraterone-acetate-and-niraparib-nature 2024-12-07T17:38:01+00:00 weekly 0.7 https://trial.medpath.com/news/bc3835357c2e06c5/roswell-park-study-reveals-how-venetoclax-boosts-immune-response-to-car-t-for 2024-12-07T17:33:58+00:00 weekly 0.7 https://trial.medpath.com/news/8a19d5b1986fe547/blueprint-medicines-continued-leadership-in-redefining-the-standard-of-care-in-systemic 2024-12-07T17:33:09+00:00 weekly 0.7 https://trial.medpath.com/news/0e04a61d932c1625/valley-doctor-receives-grant-to-help-fight-pediatric-cancer-abc30-fresno 2024-12-07T17:15:34+00:00 weekly 0.7 https://trial.medpath.com/news/b507f43a8d85d29a/nektar-s-nktr-255-achieves-breakthrough-73-response-rate-in-lymphoma-trial 2024-12-07T17:15:02+00:00 weekly 0.7 https://trial.medpath.com/news/f2c8a63479568f3e/eltrombopag-improves-outcomes-in-kids-with-newly-diagnosed-itp-medpage-today 2024-12-07T17:00:07+00:00 weekly 0.7 https://trial.medpath.com/news/e37361329322004a/phase-2-data-from-the-ongoing-hibiscus-study-shows-promise-that-investigational-morningstar 2024-12-07T16:55:48+00:00 weekly 0.7 https://trial.medpath.com/news/cea2241007064be9/beam-therapeutics-announces-new-data-from-beacon-phase-1-2-clinical-trial-yahoo-finance 2024-12-07T16:47:04+00:00 weekly 0.7 https://trial.medpath.com/news/54d10f2fe3ef4f48/bioage-shares-tumble-after-decision-to-halt-obesity-drug-study-biopharma-dive 2024-12-07T16:37:40+00:00 weekly 0.7 https://trial.medpath.com/news/fa13a6fa7458b357/the-latest-progress-in-the-application-of-telitacicept-in-autoimmune-diseases 2024-12-07T16:37:12+00:00 weekly 0.7 https://trial.medpath.com/news/f9bb83ed23e4cbfd/press-release-ash-rilzabrutinib-demonstrated-significant-globenewswire 2024-12-07T16:32:37+00:00 weekly 0.7 https://trial.medpath.com/news/3f7e115e5006bbc7/global-clinical-trial-shows-improved-survival-rates-for-common-childhood-leukemia 2024-12-07T15:09:13+00:00 weekly 0.7 https://trial.medpath.com/news/f9698e8ac72ec315/dual-targeted-car-t-yields-99-response-rate-in-pediatric-all-medpage-today 2024-12-07T15:01:21+00:00 weekly 0.7 https://trial.medpath.com/news/421422681eefb472/cdsco-waives-local-clinical-trials-for-new-drugs-approved-in-the-us-the-hindu 2024-12-07T14:58:56+00:00 weekly 0.7 https://trial.medpath.com/news/369f1b0dd87aa89e/iit-r-researchers-claim-key-insights-in-antibiotic-resistance-mechanisms-in-bacteria 2024-12-07T14:58:18+00:00 weekly 0.7 https://trial.medpath.com/news/d498fc527477d578/bioage-labs-announces-discontinuation-of-strides-phase-2-globenewswire 2024-12-07T14:50:52+00:00 weekly 0.7 https://trial.medpath.com/news/e6435189e031b919/india-s-eco-system-for-onco-clinical-trials-will-accelerate-best-in-class-drugs-for-patients 2024-12-07T14:31:10+00:00 weekly 0.7 https://trial.medpath.com/news/e65860649f142ad7/top-5-infectious-disease-news-stories-week-of-november-30-december-6-contagion-live 2024-12-07T14:10:08+00:00 weekly 0.7 https://trial.medpath.com/news/1dc0925ce37500f7/ash-2024-expert-highlights-zanubrutinib-s-sustained-efficacy-favorable-safety-profile-in-cll 2024-12-07T14:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/2dc0b97a70348539/fda-must-disclose-more-covid-19-vaccine-records-us-judge-rules-et-healthworld 2024-12-07T13:27:19+00:00 weekly 0.7 https://trial.medpath.com/news/cefe56a731fa4aa4/ratner-honored-for-career-contributions-to-nf1-research 2024-12-07T13:04:27+00:00 weekly 0.7 https://trial.medpath.com/news/d6d42da0ddfa542a/incyte-announces-positive-results-from-phase-3-trial-evaluating-retifanlimab-zynyz-r-in 2024-12-07T12:34:23+00:00 weekly 0.7 https://trial.medpath.com/news/0be01d1b1967b37e/similar-persistence-rates-between-adalimumab-new-starts-switched-patients 2024-12-07T12:03:23+00:00 weekly 0.7 https://trial.medpath.com/news/e6b4eeba3dc83ada/curis-to-report-third-quarter-2024-financial-and-operating-results-and-host-conference 2024-12-07T11:57:31+00:00 weekly 0.7 https://trial.medpath.com/news/8b9fe19d89722696/suo-2024-game-changing-team-science-urotoday 2024-12-07T11:47:15+00:00 weekly 0.7 https://trial.medpath.com/news/87d74d420ff86ec5/going-boldly-first-person-treated-in-phase-1-clinical-trial-by-alnylam-pharmaceuticals 2024-12-07T11:35:09+00:00 weekly 0.7 https://trial.medpath.com/news/8d503e05e0bed85d/repurposed-drug-has-promising-efficacy-in-non-small-cell-lung-cancer 2024-12-07T11:32:27+00:00 weekly 0.7 https://trial.medpath.com/news/d5688bd1c0ff4d32/cilcare-secures-funding-to-advance-clinical-trials-for-cochlear-synaptopathy-treatment 2024-12-07T11:23:48+00:00 weekly 0.7 https://trial.medpath.com/news/fd585a1d9b44f09f/suo-2024-exploratory-analysis-of-post-treatment-outcomes-in-patients-with-bacillus-urotoday 2024-12-07T11:06:47+00:00 weekly 0.7 https://trial.medpath.com/news/bc5e6e17394a6962/smoking-linked-to-increased-genetic-mutations-and-faster-disease-progression-in-myelodysplastic-syndromes 2024-12-07T10:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/a1c0df0bfc3dcaf4/targeting-pik3ca-with-allosteric-inhibitors-is-promising-new-approach-in-breast-cancer 2024-12-07T09:51:18+00:00 weekly 0.7 https://trial.medpath.com/news/f8557946e46eff15/world-first-urine-test-for-lung-cancer-picks-out-zombie-cells 2024-12-07T08:16:50+00:00 weekly 0.7 https://trial.medpath.com/news/b726ce8dab8558cc/ngs-and-ctdna-testing-guide-treatment-selection-and-sequencing-in-mcrc-onclive 2024-12-07T07:16:47+00:00 weekly 0.7 https://trial.medpath.com/news/0a294e3849092403/fred-hutch-research-shines-at-national-oncology-conference 2024-12-07T06:47:39+00:00 weekly 0.7 https://trial.medpath.com/news/0e1a63b0a9dd6e79/the-launch-of-spima-therapeutics-pharmaceutical-executive 2024-12-07T06:31:09+00:00 weekly 0.7 https://trial.medpath.com/news/65a089c70e5d766c/interim-analysis-highlights-long-term-safety-of-azetukalner-for-focal-epilepsy 2024-12-07T06:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/54104d46c0c9a2c5/suo-2024-co-formulated-vibostolimab-pembrolizumab-or-co-formulated-favezelimab 2024-12-07T06:06:42+00:00 weekly 0.7 https://trial.medpath.com/news/a455b40d5dbe43a9/suo-2024-a-phase-i-dose-escalation-study-of-ugn-301-zalifrelimab-as-urotoday 2024-12-07T05:45:57+00:00 weekly 0.7 https://trial.medpath.com/news/c187c117a53e2925/ethical-considerations-for-fda-accelerated-approval-the-regulatory-review 2024-12-07T05:34:27+00:00 weekly 0.7 https://trial.medpath.com/news/de20b24e3fc58d19/astrazeneca-daiichi-build-cancer-drug-case-amgen-invests-1b-biopharma-dive 2024-12-07T04:15:02+00:00 weekly 0.7 https://trial.medpath.com/news/420dadc1935dcdea/long-term-data-on-olanzapine-and-samidorphan-highlight-maintained-schizophrenia 2024-12-07T01:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/20e9fed66a9be928/protara-cg-oncology-tout-promising-bladder-cancer-outcomes-biospace 2024-12-07T00:46:24+00:00 weekly 0.7 https://trial.medpath.com/news/2c0ad7e8f451cbed/ucsf-health-experts-spotlight-advances-at-hematology-conference-uc-san-francisco 2024-12-07T00:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/95cc23cd5d07b4fb/phase-2-study-shows-promise-for-zanubrutinib-and-venetoclax-combination-in-r-r-cll 2024-12-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1e156dd7072f2159/feasibility-of-simon-2-stage-futility-trials-in-early-parkinson-disease-pubmed 2024-12-06T23:56:09+00:00 weekly 0.7 https://trial.medpath.com/news/e9c0c55dfa697af0/suo-2024-mk-5684-003-a-phase-3-study-of-cyp11a1-inhibitor-opevesostat-versus-next 2024-12-06T22:24:30+00:00 weekly 0.7 https://trial.medpath.com/news/55ea5752140055e6/confirmatory-trials-us-fda-toughens-stance-on-need-for-advance-planning-due-diligence 2024-12-06T22:22:52+00:00 weekly 0.7 https://trial.medpath.com/news/d4b106ab5a50c0ca/phase-ii-trial-shows-decreased-lung-volume-in-nsclc-heightens-pneumonitis-risk 2024-12-06T22:16:50+00:00 weekly 0.7 https://trial.medpath.com/news/de008e4cea4da67f/dr-liu-on-the-trust-ii-trial-of-taletrectinib-in-ros1-nsclc-onclive 2024-12-06T22:16:41+00:00 weekly 0.7 https://trial.medpath.com/news/731f425daac008a2/dr-stearns-on-the-role-of-carboplatin-in-early-stage-tnbc-onclive 2024-12-06T22:16:41+00:00 weekly 0.7 https://trial.medpath.com/news/72cc5cf8dac0a609/enanta-pharma-to-unveil-breakthrough-rsv-pediatric-trial-results-key-phase-2-data-coming 2024-12-06T22:13:10+00:00 weekly 0.7 https://trial.medpath.com/news/49e3712eeb738efb/drs-baljevic-and-cortes-preview-upcoming-studies-and-emerging-data-from-ash-2024 2024-12-06T22:12:26+00:00 weekly 0.7 https://trial.medpath.com/news/4f27e0cf7d663e86/suo-2024-clinical-progression-of-prostate-cancer-from-active-surveillance-is-predicted-by 2024-12-06T21:51:29+00:00 weekly 0.7 https://trial.medpath.com/news/e1f18ba73a99ca9a/patent-highlights-usp19-inhibitors-kcc2-potentiators-nrf2-inhibitors-additional-polth-inhibitors-and-more 2024-12-06T21:38:51+00:00 weekly 0.7 https://trial.medpath.com/news/426421b8c0f3eaa5/iron-deficiency-anemia-therapeutics-market-size-in-the-7mm-was-around-the-globe-and-mail 2024-12-06T21:10:39+00:00 weekly 0.7 https://trial.medpath.com/news/bb110ca9f1370675/phase-one-trial-explores-novel-immunotherapy-for-breast-cancer-news-medical 2024-12-06T21:02:56+00:00 weekly 0.7 https://trial.medpath.com/news/929c3d998186f0a3/sana-biotechnology-stock-hits-52-week-low-at-2-29-investing-com 2024-12-06T20:57:09+00:00 weekly 0.7 https://trial.medpath.com/news/1b8c37e7fa8b9994/syntheticmr-receives-fda-510-k-clearance-for-symri-15-pr-newswire 2024-12-06T20:55:47+00:00 weekly 0.7 https://trial.medpath.com/news/bd0c6237dc3340dd/ajmc-r-in-the-press-december-6-2024 2024-12-06T20:54:50+00:00 weekly 0.7 https://trial.medpath.com/news/44031644226f99b2/fda-roundup-december-6-2024-longview-news-journal 2024-12-06T20:42:02+00:00 weekly 0.7 https://trial.medpath.com/news/5e00e5ebee4904bd/ucb-eyes-two-more-approvals-after-this-year-s-success-hiteunyuseu 2024-12-06T20:17:35+00:00 weekly 0.7 https://trial.medpath.com/news/87644e7742bdedd2/duality-biologics-and-biontech-presented-positive-interim-data-for-investigational-b7-h3 2024-12-06T19:57:31+00:00 weekly 0.7 https://trial.medpath.com/news/48973f9f98cd55fb/can-immunotherapy-go-the-distance-in-es-ls-small-cell-lung-cancer-medpage-today 2024-12-06T19:05:39+00:00 weekly 0.7 https://trial.medpath.com/news/76f96ad8a0870c0d/community-cancer-centers-face-implementation-hurdles-with-bispecific-antibody-therapies 2024-12-06T19:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/8d456173b63631c8/pivot-006-phase-iii-trial-of-creto-vs-surveillance-in-intermediate-risk-bladder-cancer-mark-tyson 2024-12-06T19:01:19+00:00 weekly 0.7 https://trial.medpath.com/news/50df3c90ac589f82/biohaven-s-novel-epilepsy-drug-shows-breakthrough-safety-profile-in-clinical-trials 2024-12-06T17:57:33+00:00 weekly 0.7 https://trial.medpath.com/news/62231340c50f6f77/vision-rehabilitation-research-the-reporter-uab 2024-12-06T17:52:36+00:00 weekly 0.7 https://trial.medpath.com/news/0fe44e3716541200/new-data-supporting-a-new-precision-medicine-approach-for-als-patients-with-geneuro-s 2024-12-06T17:43:26+00:00 weekly 0.7 https://trial.medpath.com/news/4bfbdfe39299d710/breakthrough-clinical-study-proves-traya-customized-regimen-delivers-3-times-better-results 2024-12-06T17:31:44+00:00 weekly 0.7 https://trial.medpath.com/news/4f7295d9a6300530/copan-diagnostics-announces-fda-clearance-for-innovative-urine-collection-device 2024-12-06T17:28:04+00:00 weekly 0.7 https://trial.medpath.com/news/0eb28b86e64420cd/jak-inhibitor-comes-up-short-in-phase-iii-crohn-s-disease-trial-medpage-today 2024-12-06T17:25:20+00:00 weekly 0.7 https://trial.medpath.com/news/f60ce03f43871fb6/identifying-a-clinical-stage-small-molecule-yap-taz-tead-ppi-inhibitor-from-a-natural-yap-o-loop-peptide 2024-12-06T17:14:58+00:00 weekly 0.7 https://trial.medpath.com/news/c48e2e825acfab02/phase-4-epicom-study-highlights-potential-of-cbd-in-neuropsychiatric-disorders-of 2024-12-06T17:02:13+00:00 weekly 0.7 https://trial.medpath.com/news/7d01279e4dbdca59/fostamatinib-fails-to-improve-outcomes-in-hypoxemic-covid-patients-medpage-today 2024-12-06T16:36:48+00:00 weekly 0.7 https://trial.medpath.com/news/d087ae8eb13d4b61/bioarctic-doses-first-subject-in-parkinson-s-disease-therapy-trial 2024-12-06T16:01:12+00:00 weekly 0.7 https://trial.medpath.com/news/b91a6385a7d82f6a/breakthrough-in-breast-cancer-progression-drug-resistance-mirage-news 2024-12-06T15:59:52+00:00 weekly 0.7 https://trial.medpath.com/news/7c777c83be71ad80/indapta-therapeutics-announces-clinical-study-collaboration-with-sanofi-on-multiple 2024-12-06T15:50:07+00:00 weekly 0.7 https://trial.medpath.com/news/b4ec4ec335080107/atlas-closes-450m-biotech-fund-and-other-financing-news-pharmaphorum 2024-12-06T15:43:09+00:00 weekly 0.7 https://trial.medpath.com/news/8033e2811038471e/ovarian-cancer-imaging-approach-could-enable-personalized-treatment-almost-immediately 2024-12-06T15:34:05+00:00 weekly 0.7 https://trial.medpath.com/news/44b06bd0dc00936e/chronic-pseudomonas-aeruginosa-pulmonary-infections-pipeline-insight-2024-globenewswire 2024-12-06T15:14:57+00:00 weekly 0.7 https://trial.medpath.com/news/a3671c3bb68fadf5/steps-taken-by-the-government-to-promote-research-development-and-deployment-of-car-pib 2024-12-06T14:35:25+00:00 weekly 0.7 https://trial.medpath.com/news/2e8e68f6b27c0891/updated-recommendation-for-universal-hepatitis-b-vaccination-in-adults-aged-19-59-years-cdc 2024-12-06T14:11:52+00:00 weekly 0.7 https://trial.medpath.com/news/311d330f431c4396/jaguar-health-launches-major-clinical-trial-for-orphan-drug-crofelemer-in-short-bowel-syndrome 2024-12-06T13:55:35+00:00 weekly 0.7 https://trial.medpath.com/news/e58744f82c4dfe0d/opioids-interfere-with-cancer-immunotherapy-but-these-drugs-could-help 2024-12-06T13:28:56+00:00 weekly 0.7 https://trial.medpath.com/news/87028fe0784fc442/verrica-s-partner-files-nda-in-japan-for-breakthrough-molluscum-treatment-stock-titan 2024-12-06T13:15:41+00:00 weekly 0.7 https://trial.medpath.com/news/7bd01d1b80dd1f9c/fluorescent-imaging-technology-expedites-thoracic-surgery-in-lung-cancer 2024-12-06T13:05:27+00:00 weekly 0.7 https://trial.medpath.com/news/a35187d3c313ab43/opus-genetics-inc-to-share-6-month-efficacy-and-safety-data-on-opgx-lca5 2024-12-06T12:51:06+00:00 weekly 0.7 https://trial.medpath.com/news/927b22b1f904aa29/adc-therapeutics-to-provide-initial-data-update-on-lotis-7-clinical-trial-yahoo-finance 2024-12-06T12:42:52+00:00 weekly 0.7 https://trial.medpath.com/news/339e2228de581716/fda-grants-orphan-drug-designation-to-novel-gene-therapy-for-fabry-disease 2024-12-06T11:48:38+00:00 weekly 0.7 https://trial.medpath.com/news/b8d6e7034133765b/centerline-biomedical-receives-us-fda-510-k-clearance-for-its-new-iops-guidewire 2024-12-06T11:31:51+00:00 weekly 0.7 https://trial.medpath.com/news/7800ded07730336a/new-therapy-helps-patients-with-tough-to-treat-bladder-cancers 2024-12-06T11:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/486d048bb3e590cc/bostonsight-publishes-pilot-study-on-prose-scleral-lenses-as-a-drug-delivery-system-for 2024-12-06T11:06:50+00:00 weekly 0.7 https://trial.medpath.com/news/c158803428ffd8ee/summary-report-on-authorisation-tegsedi-r-swissmedic 2024-12-06T10:28:41+00:00 weekly 0.7 https://trial.medpath.com/news/06d63317231bb284/summary-report-on-authorisation-qdenga-r-swissmedic 2024-12-06T10:28:25+00:00 weekly 0.7 https://trial.medpath.com/news/749e5047ce2073a9/hiv-aids-awareness-month-2024-looking-back-at-progress-in-gene-therapy-and-gene-editing 2024-12-06T09:17:35+00:00 weekly 0.7 https://trial.medpath.com/news/e83bc0730e776755/galimedix-therapeutics-initiates-phase-1-trial-of-oral-gal-101 2024-12-06T09:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/3dccdf90e54a40e7/florida-cancer-specialists-research-institute-building-knowledge-and-improving-pr-newswire 2024-12-06T08:48:10+00:00 weekly 0.7 https://trial.medpath.com/news/b42eea0b4d80bac0/ai-adoption-in-pharma-r-d-reaches-49-icon-survey-reveals-growing-industry-confidence 2024-12-06T08:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/0c6e76ccdb5f7cf8/finding-hope-with-antibody-drug-conjugates-in-managing-breast-cancer-cure-today 2024-12-06T08:04:07+00:00 weekly 0.7 https://trial.medpath.com/news/6b1f0335bfd2d22c/ugn-102-showed-promising-long-term-results-in-the-phase-3-envision-trial-potentially 2024-12-06T07:25:48+00:00 weekly 0.7 https://trial.medpath.com/news/4acaffa5f88ef93e/suo-2024-trial-design-for-bcg-unresponsive-nmibc-time-to-move-past-single-arm 2024-12-06T06:55:14+00:00 weekly 0.7 https://trial.medpath.com/news/8e2ea314a665889e/innate-pharma-secures-7-9m-partnership-deal-for-lymphoma-drug-development 2024-12-06T06:48:06+00:00 weekly 0.7 https://trial.medpath.com/news/efba36289cbcc883/dbv-upbeat-on-allergy-patch-studies-approval-chances-allergic-living 2024-12-06T06:39:24+00:00 weekly 0.7 https://trial.medpath.com/news/cd65ea1d9adf1d85/new-phase-iiib-data-shows-novartis-fabhalta-r-improved-globenewswire 2024-12-06T06:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/cc0f2b0f503db951/diversity-equity-and-inclusion-guidelines-still-not-optimal-for-hiv-positive-patients 2024-12-06T06:00:01+00:00 weekly 0.7 https://trial.medpath.com/news/3e89083a4dd9266c/sulthiame-shows-promise-in-treating-obstructive-sleep-apnea-leads-ers-congress-2024-highlights 2024-12-06T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7103798bd1b29185/is-it-time-to-approve-drugs-based-on-amyloid-removal-alzforum 2024-12-06T05:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/056f88cf302a44ea/addition-of-cadonilimab-improves-survival-in-advanced-cervical-cancer-oncology-nursing-news 2024-12-06T05:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/c86f063c6c9e6ccb/fda-releases-draft-on-accelerated-approvals-for-drugs-biologics-bloomberg-law-news 2024-12-06T04:37:21+00:00 weekly 0.7 https://trial.medpath.com/news/271bda58978c9889/pharmac-funds-new-cancer-rsv-copd-treatments-rnz-news 2024-12-06T04:36:38+00:00 weekly 0.7 https://trial.medpath.com/news/d7994f4c1d4a189a/tpf-participation-department-of-transportation-commonwealth-of-pennsylvania 2024-12-06T04:36:23+00:00 weekly 0.7 https://trial.medpath.com/news/efa44e40e9f5528f/technology-revolutionizes-patient-registries-enhanced-real-world-evidence-collection-through-digital-innovation 2024-12-06T03:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/68a4ba3566220e51/comparing-models-that-integrate-obstetric-care-and-wic-on-improved-program-enrollment 2024-12-06T03:13:54+00:00 weekly 0.7 https://trial.medpath.com/news/0a6943c927cd312d/nuvalent-s-swot-analysis-promising-pipeline-drives-stock-outlook-investing-com 2024-12-06T03:00:22+00:00 weekly 0.7 https://trial.medpath.com/news/1011cc1018b7620a/studies-show-more-promising-results-for-rsv-drug-nirsevimab-cidrap 2024-12-06T03:00:18+00:00 weekly 0.7 https://trial.medpath.com/news/f7aa2765bab33097/major-treg-summit-to-showcase-latest-advances-in-autoimmune-disease-treatment-development 2024-12-06T02:36:46+00:00 weekly 0.7 https://trial.medpath.com/news/85a2fb1817778d26/suo-2024-strategies-for-rplnd-in-metastatic-testicular-seminoma-urotoday 2024-12-06T01:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/f34344bab5f66981/affimed-announces-acimtamig-and-allonk-r-combination-granted-globenewswire 2024-12-05T23:31:46+00:00 weekly 0.7 https://trial.medpath.com/news/1197e9d5a092d8e6/medicinova-presents-study-update-and-interim-analysis-of-phase-2-3-clinical-trial-of-mn 2024-12-05T23:12:16+00:00 weekly 0.7 https://trial.medpath.com/news/955dd3c91fdd0a82/kalvista-pharmaceuticals-inc-sec-10-q-report-tradingview 2024-12-05T22:36:47+00:00 weekly 0.7 https://trial.medpath.com/news/793ffa9b7370f05d/fda-grants-ns-050-ncnp-03-rare-pediatric-disease-designation-in-duchenne-muscular-dystrophy 2024-12-05T22:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/2c94739cec3fd821/suo-2024-sunrise-5-a-phase-iii-randomized-open-label-study-of-tar-200-compared 2024-12-05T22:05:40+00:00 weekly 0.7 https://trial.medpath.com/news/d92fc9e0c0f9cca7/brief-everest-unveils-positive-results-for-kidney-drug-ever001-in-phase-1b-2a-trial 2024-12-05T21:38:27+00:00 weekly 0.7 https://trial.medpath.com/news/9d3911c98be0b861/bcm-receives-3-5-million-to-study-telehealth-genetic-services-for-sick-underserved-newborns 2024-12-05T21:09:28+00:00 weekly 0.7 https://trial.medpath.com/news/d722b187db593420/fda-approves-new-formulation-of-pazopanib-tablets-in-rcc-sarcoma-cancer-network 2024-12-05T20:25:26+00:00 weekly 0.7 https://trial.medpath.com/news/3732128cfa4a4515/how-the-healy-als-platform-trial-is-helping-to-accelerate-the-pathway-to-new-als-treatments 2024-12-05T20:22:39+00:00 weekly 0.7 https://trial.medpath.com/news/410ad84d4064af51/research-roundup-the-latest-science-discoveries-and-breakthroughs 2024-12-05T20:04:16+00:00 weekly 0.7 https://trial.medpath.com/news/78e22ed418bc9eb3/lungpacer-medical-announces-premarket-approval-for-aeropace-r-system-biospace 2024-12-05T19:53:23+00:00 weekly 0.7 https://trial.medpath.com/news/110a2756fd88ff9b/tilt-biotherapeutics-provides-update-on-international-clinical-trial-progress-with-biospace 2024-12-05T19:53:14+00:00 weekly 0.7 https://trial.medpath.com/news/add5a833b6707a8d/nuvig-pulls-in-161m-to-make-better-immune-drugs-biopharma-dive 2024-12-05T19:53:13+00:00 weekly 0.7 https://trial.medpath.com/news/f815f9bb41db20bc/protera-therapeutics-stock-remains-buy-rated-after-promising-tara-002-phase-ii-results 2024-12-05T19:28:36+00:00 weekly 0.7 https://trial.medpath.com/news/377ee31808c494fb/rochester-regional-health-s-sands-constellation-heart-institute-becomes-first-u-s-site-for 2024-12-05T19:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/7d0afd6d2e98c912/immunotherapy-redefines-standard-of-care-for-frontline-advanced-endometrial-cancer 2024-12-05T19:05:47+00:00 weekly 0.7 https://trial.medpath.com/news/312304754a3f4dd1/cytokine-tv-implantable-protein-sensors-monitor-live-inflammation 2024-12-05T19:02:53+00:00 weekly 0.7 https://trial.medpath.com/news/8b88e7a0ff6cd067/maat-pharma-sa-announces-first-u-s-patient-treated-at-city-of-hope-under-marketscreener 2024-12-05T19:01:51+00:00 weekly 0.7 https://trial.medpath.com/news/48acc2aeaa7125f1/new-drug-tested-to-reduce-side-effect-of-half-matched-stem-cell-transplants 2024-12-05T18:46:50+00:00 weekly 0.7 https://trial.medpath.com/news/1614d8714fb0857f/epicentrx-s-oncolytic-virus-delivered-tgfb-inhibitor-adapt-001-receives-fda-fast-track 2024-12-05T18:45:59+00:00 weekly 0.7 https://trial.medpath.com/news/e8b6004da0106ae5/strong-safety-nuanced-efficacy-results-for-canakinumab-in-previously-treated-mds 2024-12-05T18:29:59+00:00 weekly 0.7 https://trial.medpath.com/news/7d7fafb4581acfd0/long-term-efficacy-of-first-line-afatinib-and-the-clinical-utility-of-ctdna-monitoring-in-patients 2024-12-05T18:28:37+00:00 weekly 0.7 https://trial.medpath.com/news/1875f9e9e78484fe/lundbeck-highlights-commitment-to-the-rare-epilepsy-community-at-american-cision-news 2024-12-05T18:08:47+00:00 weekly 0.7 https://trial.medpath.com/news/d36962fc693e2143/rubi-secures-1-million-phase-ii-grant-from-the-national-science-foundation-to-scale-its 2024-12-05T17:50:39+00:00 weekly 0.7 https://trial.medpath.com/news/2eff22330d5da3af/evaluation-of-a-mobile-application-to-decrease-opioid-misuse-in-patients-undergoing 2024-12-05T17:31:51+00:00 weekly 0.7 https://trial.medpath.com/news/2d553079eef9f110/the-long-journey-of-a-small-molecule-of-hope-research-horizons 2024-12-05T17:26:09+00:00 weekly 0.7 https://trial.medpath.com/news/371c72219d43e4ff/study-finds-tonsil-removal-not-linked-to-weight-gain-contrary-to-popular-belief-michigan-medicine 2024-12-05T16:05:12+00:00 weekly 0.7 https://trial.medpath.com/news/9e1f98230fd6f445/december-5-2024-nudge-pragmatic-trial-finds-no-improvement-in-adherence-to 2024-12-05T15:44:52+00:00 weekly 0.7 https://trial.medpath.com/news/9238d46a7b3d32d1/simcha-therapeutics-announces-the-opening-of-two-clinical-studies-exploring-st-067-in 2024-12-05T15:31:45+00:00 weekly 0.7 https://trial.medpath.com/news/367d1ca87a3c1998/unlearn-and-apst-research-partner-to-build-high-quality-dataset-to-accelerate-als-clinical-trials 2024-12-05T15:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/eac533cf71fae3dd/suo-2024-in-depth-characterization-of-the-safety-profile-of-belzutifan-monotherapy-in-urotoday 2024-12-05T15:15:16+00:00 weekly 0.7 https://trial.medpath.com/news/35a649dca8005ad0/clinical-trial-eligibility-and-outcomes-in-patients-with-metastatic-nsclc-treated-outside-of 2024-12-05T15:05:10+00:00 weekly 0.7 https://trial.medpath.com/news/abba9a0fb4837829/ryvu-therapeutics-announces-dosing-of-the-first-patient-in-the-potami-61-phase-ii-study 2024-12-05T14:53:26+00:00 weekly 0.7 https://trial.medpath.com/news/aa61280dc99cde9a/protara-therapeutics-inc-announces-positive-results-from-the-ongoing-phase-2-advanced 2024-12-05T14:49:25+00:00 weekly 0.7 https://trial.medpath.com/news/acd85d53ff4aa182/her2-gastric-cancer-market-report-2032-epidemiology-openpr-com 2024-12-05T14:47:38+00:00 weekly 0.7 https://trial.medpath.com/news/6b39711b829bd7af/mission-bio-showcases-critical-insights-into-multiple-myeloma-aml-mrd-car-t-safety 2024-12-05T14:39:22+00:00 weekly 0.7 https://trial.medpath.com/news/3ce6b0fd4b4218ff/simx-receives-1-25m-phase-ii-sttr-grant-from-afwerx-to-advance-vr-training-for 2024-12-05T13:52:57+00:00 weekly 0.7 https://trial.medpath.com/news/e8b6594af7da3e03/cu-cancer-center-member-breelyn-wilky-md-oversees-trial-of-new-treatment-for-sarcomas 2024-12-05T13:36:45+00:00 weekly 0.7 https://trial.medpath.com/news/254aeace975cf908/aurobindo-pharma-wins-usfda-approval-for-generic-cancer-drug-the-hindu-businessline 2024-12-05T13:09:46+00:00 weekly 0.7 https://trial.medpath.com/news/c5501629872c68c7/suo-2024-disease-free-survival-and-overall-survival-in-patients-with-high-risk-muscle 2024-12-05T13:09:17+00:00 weekly 0.7 https://trial.medpath.com/news/138ec88f21e5ab08/annexon-to-present-phase-2-archer-data-on-protection-of-globenewswire 2024-12-05T13:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/3c5e03b810595aca/theriva-biologics-gets-fda-guidance-on-vcn-01-phase-3-trial-design-for-pancreatic 2024-12-05T13:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/78217d35ef121c75/denali-therapeutics-launches-key-phase-2a-trial-for-breakthrough-parkinson-s-treatment 2024-12-05T13:02:03+00:00 weekly 0.7 https://trial.medpath.com/news/f9c2fc79d53d2750/imfinzi-approved-in-the-us-as-first-and-only-immunotherapy-regimen-for-patients-with-limited 2024-12-05T13:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/45d4f22e87a3c7e3/single-versus-tandem-autologous-stem-cell-transplantation-in-newly-diagnosed-multiple-myeloma 2024-12-05T12:41:36+00:00 weekly 0.7 https://trial.medpath.com/news/c52805131219e58d/theralase-r-launches-new-clinical-study-site-in-canada-corsicana-daily-sun 2024-12-05T12:22:53+00:00 weekly 0.7 https://trial.medpath.com/news/727d3d2ef34ddff4/yap1-and-kras-identified-as-key-drivers-in-soft-tissue-sarcoma-development-opening-new-treatment-avenues 2024-12-05T12:19:35+00:00 weekly 0.7 https://trial.medpath.com/news/278c2877b343925c/the-us-fda-approves-ibox-french-algorithm-for-predicting-kidney-graft-survival 2024-12-05T12:11:47+00:00 weekly 0.7 https://trial.medpath.com/news/f9db1690d19c5bca/ntc-presents-positive-results-from-phase-ii-mirakle-study-evaluating-an-innovative-drug-for 2024-12-05T11:56:19+00:00 weekly 0.7 https://trial.medpath.com/news/8b05edb4f6453628/merck-and-ridgeback-biotherapeutics-announce-initiation-of-phase-3-study-move-now 2024-12-05T11:50:10+00:00 weekly 0.7 https://trial.medpath.com/news/fb42a7c56846d2cc/kalvista-pharmaceuticals-reports-second-fiscal-quarter-results-and-provides-operational-update 2024-12-05T11:35:35+00:00 weekly 0.7 https://trial.medpath.com/news/0732106c05ec0555/most-young-people-with-long-covid-recover-within-2-years 2024-12-05T11:12:20+00:00 weekly 0.7 https://trial.medpath.com/news/84063818bbbba17b/nanox-secures-major-fda-clearance-expansion-for-revolutionary-digital-x-ray-system 2024-12-05T11:03:36+00:00 weekly 0.7 https://trial.medpath.com/news/77e71a17aea5773f/media-advisory-abnormal-prenatal-blood-test-results-could-indicate-hidden-maternal-cancers 2024-12-05T10:04:13+00:00 weekly 0.7 https://trial.medpath.com/news/784d2cf7464c4a9a/clinical-trial-outsourcing-market-set-to-reach-91-2-billion-by-2034-driven-by-technology-integration-and-strategic-partnerships 2024-12-05T09:31:39+00:00 weekly 0.7 https://trial.medpath.com/news/ca7ba14c08467395/safety-and-effectiveness-of-transcutaneous-auricular-vagus-nerve-stimulation-on-patients 2024-12-05T09:26:52+00:00 weekly 0.7 https://trial.medpath.com/news/3fb5d7712869b181/uk-first-country-in-europe-to-reimburse-tirzepatide-european-biotechnology-magazine 2024-12-05T09:21:52+00:00 weekly 0.7 https://trial.medpath.com/news/4685d893a8551da7/who-senior-adviser-calls-for-systematic-reviews-to-address-clinical-trial-diversity-gap 2024-12-05T08:59:25+00:00 weekly 0.7 https://trial.medpath.com/news/ec52baf25f2e3e8f/avistone-announces-updates-on-ans03-biospace 2024-12-05T08:25:09+00:00 weekly 0.7 https://trial.medpath.com/news/0adc0c7a34f530e8/3-asx-biotech-shares-rocketing-10-to-26-on-big-news-motley-fool 2024-12-05T08:09:30+00:00 weekly 0.7 https://trial.medpath.com/news/cc14130ff224aaa7/first-cd20xcd3-antibody-shows-survival-benefits-in-phase-iii-lymphoma-trial-rhhby-stock-news 2024-12-05T08:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/4933caf28f76dc8d/theralase-technologies-inc-tltff-q3-2024-earnings-call-highlig-gurufocus 2024-12-05T07:28:34+00:00 weekly 0.7 https://trial.medpath.com/news/0e7fd483b6ea63d1/physiomics-secures-new-contract-with-numab-therapeutics-for-inflammation-study 2024-12-05T07:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/c20a29cc31ea2e05/ips-test-shows-promise-in-guiding-immunotherapy-decisions-for-solid-tumor-treatment 2024-12-05T07:01:43+00:00 weekly 0.7 https://trial.medpath.com/news/3e592950c7610d19/cyp-006tk-demonstrates-safety-and-efficacy-in-dfu-clinical-trial-biospace 2024-12-05T06:48:02+00:00 weekly 0.7 https://trial.medpath.com/news/eb8e83cc2472487e/acrux-gains-fda-approval-and-raises-2-65-million-markets-insider 2024-12-05T06:46:01+00:00 weekly 0.7 https://trial.medpath.com/news/2e9b283488f69fde/nxera-pharma-enrolls-first-insomnia-patient-in-its-phase-3-globenewswire 2024-12-05T06:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/2fa5f9e813a5b302/breakthrough-advances-in-lung-cancer-treatment-combine-early-detection-and-personalized-therapies 2024-12-05T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7495722eab60a437/gut-microbiota-modulation-a-novel-mechanism-in-arb-mediated-hypertension-treatment 2024-12-05T05:56:08+00:00 weekly 0.7 https://trial.medpath.com/news/52fd271c9df5b2ae/anatara-provides-irritable-bowel-syndrome-clinical-trial-update-biotech-dispatch 2024-12-05T05:23:09+00:00 weekly 0.7 https://trial.medpath.com/news/7193e20ef5ac92ff/how-bad-is-fraud-in-alzheimer-s-research-q-a-with-neurologist-sleuth-matthew-schrag 2024-12-05T05:17:26+00:00 weekly 0.7 https://trial.medpath.com/news/f4b023e81ea3316e/durvalumab-wins-fda-approval-in-limited-stage-small-cell-lung-cancer 2024-12-05T04:59:33+00:00 weekly 0.7 https://trial.medpath.com/news/f0f6ae561e08322b/edgewise-therapeutics-swot-analysis-biotech-stock-poised-for-growth-amid-clinical-milestones 2024-12-05T04:44:11+00:00 weekly 0.7 https://trial.medpath.com/news/1fd54a78f5b01854/us-abortion-laws-could-deter-women-s-participation-in-clinical-research-raising-scientific-and-ethical-concerns 2024-12-05T04:38:17+00:00 weekly 0.7 https://trial.medpath.com/news/7b9d15c197b823cd/how-cedars-sinai-increased-black-and-hispanic-clinical-trial-enrollment-blackdoctor-org 2024-12-05T04:10:59+00:00 weekly 0.7 https://trial.medpath.com/news/87d9d2efba27924e/terns-pharmaceuticals-allosteric-inhibitor-shows-best-in-class-potential-in-phase-i-cml-study 2024-12-05T04:07:05+00:00 weekly 0.7 https://trial.medpath.com/news/8cd80ed9b03b52e1/tirzepatide-shows-47-greater-weight-loss-than-semaglutide-in-72-week-phase-3b-study 2024-12-05T03:54:55+00:00 weekly 0.7 https://trial.medpath.com/news/d3e0ed4dc079da13/appeals-court-denies-novartis-bid-to-block-generic-entresto-threatening-5-6b-revenue-stream 2024-12-05T03:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/71796f38a27950ca/matica-biotechnology-partners-with-treovir-on-hsv-vectors-for-pediatric-brain-tumor-therapy 2024-12-05T01:35:33+00:00 weekly 0.7 https://trial.medpath.com/news/ca390090a5cfbd58/pancreatic-cancer-patient-survival-doubled-with-high-dose-of-common-vitamin-study-finds 2024-12-05T00:51:13+00:00 weekly 0.7 https://trial.medpath.com/news/8a125712745c9ce6/suo-2024-real-world-treatment-and-clinical-outcomes-in-patients-with-mcrpc-treated 2024-12-05T00:29:28+00:00 weekly 0.7 https://trial.medpath.com/news/ad9cab629ac3a16e/high-tumor-mutational-burden-linked-to-improved-survival-in-metastatic-colon-cancer 2024-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b20e624032683571/singapore-launches-25-million-clarion-program-to-transform-asian-lung-cancer-treatment 2024-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/37f10b11fefecee4/singapore-leads-asia-in-groundbreaking-gene-editing-trial-for-rare-heart-disease 2024-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5f4fb7173f151e77/lenvatinib-pembrolizumab-vs-chemotherapy-in-advanced-endometrial-cancer 2024-12-04T23:45:10+00:00 weekly 0.7 https://trial.medpath.com/news/c6686b3e2501730c/can-fite-announces-8-year-survival-for-patient-in-phase-2-liver-cancer-study 2024-12-04T23:41:05+00:00 weekly 0.7 https://trial.medpath.com/news/1bd51a22a51079de/fda-grants-rare-pediatric-disease-to-101-pgc-005-for-systemic-juvenile-idiopathic-arthritis 2024-12-04T23:37:29+00:00 weekly 0.7 https://trial.medpath.com/news/e138f32fd350bb92/fda-grants-revascor-r-rexlemestrocel-l-regenerative-globenewswire 2024-12-04T23:36:34+00:00 weekly 0.7 https://trial.medpath.com/news/ae3f668d0cb31248/race-oncology-advances-rc220-phase-1-cancer-trial-tipranks-com 2024-12-04T22:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/79f6d2b9c562b4a4/editorial-hong-kong-drug-trials-institute-a-healthy-step-forward 2024-12-04T22:18:12+00:00 weekly 0.7 https://trial.medpath.com/news/4498d61acfdc6dda/novel-heart-stent-for-kids-draws-praise-research-horizons 2024-12-04T22:17:30+00:00 weekly 0.7 https://trial.medpath.com/news/76dcbc4cf7842a39/breaking-new-ground-in-immunology-inflammation-inside-precision-medicine 2024-12-04T22:17:21+00:00 weekly 0.7 https://trial.medpath.com/news/f7c5c64553b4c80b/suo-2024-mevrometostat-pf-06821497-in-combination-with-enzalutamide-in-patients 2024-12-04T22:04:04+00:00 weekly 0.7 https://trial.medpath.com/news/296f29a7ec6dfbf6/biotech-startup-avoids-sec-penalties-through-voluntary-self-report-legal-dive 2024-12-04T22:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/9fb6ec04045c0acd/corvus-pharma-s-cancer-drug-shows-breakthrough-immune-response-in-nature-journal-study 2024-12-04T21:14:24+00:00 weekly 0.7 https://trial.medpath.com/news/f1643d8f5cea76e8/penn-state-college-of-medicine-beat-childhood-cancer-research-consortium-leading 2024-12-04T20:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/9a86e4549125d97c/eyepoint-doses-first-patient-in-second-global-phase-3-lucia-clinical-trial-of-duravyu-for-the 2024-12-04T20:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/13bb50a5de365fa2/fda-finalizes-pccp-guidance-for-ai-enabled-medical-devices-akin-gump 2024-12-04T19:13:18+00:00 weekly 0.7 https://trial.medpath.com/news/d2dfbed71be65530/ngs-and-novel-therapies-lends-to-prolonged-survival-outcomes-in-hr-her2-breast-cancer 2024-12-04T19:11:14+00:00 weekly 0.7 https://trial.medpath.com/news/200e6467b385672e/what-to-know-about-metastatic-prostate-cancer 2024-12-04T19:02:27+00:00 weekly 0.7 https://trial.medpath.com/news/40cfe2af27bbc485/all-leukemia-clinical-studies-ongoing-recruitment-and-more-medicalnewstoday 2024-12-04T18:45:28+00:00 weekly 0.7 https://trial.medpath.com/news/3e5a2f96c17c99ba/phanes-therapeutics-pt217-granted-fast-track-designation-by-the-fda-for-nepc 2024-12-04T18:42:07+00:00 weekly 0.7 https://trial.medpath.com/news/488caf1b0416be60/impact-of-prior-dengue-infection-on-severity-and-outcomes-meta-analysis-of-placebo-controlled-trials 2024-12-04T18:42:06+00:00 weekly 0.7 https://trial.medpath.com/news/553bb403b0f1d98f/restem-receives-fda-orphan-drug-designation-for-its-ulsc-program-for-the-treatment-of 2024-12-04T18:39:32+00:00 weekly 0.7 https://trial.medpath.com/news/c311c5b0687a39e9/sinai-health-s-innovative-clinical-trial-framework-leads-to-transformative-advances-in 2024-12-04T18:16:21+00:00 weekly 0.7 https://trial.medpath.com/news/ee90ad7547d7ef8a/ultrasound-controlled-crispr-offers-precision-in-treating-genetic-disorders-news-medical 2024-12-04T18:15:15+00:00 weekly 0.7 https://trial.medpath.com/news/d36c859cf180390d/initial-safety-findings-reported-on-luspatercept-plus-lenalidomide-for-non-del-5q-mds 2024-12-04T18:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/31a510f2b7faa1f7/dewpoint-mitsubishi-partner-on-als-drug-in-deal-worth-up-to-480m-biopharma-dive 2024-12-04T18:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/49a7a9a9c0359fd0/phase-ii-iii-pooled-data-analysis-imetelstat-benefit-in-mds-independent-of-prior-therapy 2024-12-04T17:51:09+00:00 weekly 0.7 https://trial.medpath.com/news/ec5526aa85f77c53/toripalimab-plus-chemotherapy-in-first-line-therapy-for-extensive-stage-small-cell-lung-cancer 2024-12-04T17:50:37+00:00 weekly 0.7 https://trial.medpath.com/news/edacc08b78a9d57a/md-anderson-research-highlights-ash-2024-special-edition 2024-12-04T17:39:35+00:00 weekly 0.7 https://trial.medpath.com/news/b0d392349baca3ca/health-net-grant-for-uc-davis-stem-cell-program-to-improve-access-to-car-t-cell-therapy 2024-12-04T17:34:43+00:00 weekly 0.7 https://trial.medpath.com/news/3fd8a077375d53c5/review-highlights-gaps-in-publicly-funded-non-inferiority-clinical-trials-call-for-better 2024-12-04T17:17:22+00:00 weekly 0.7 https://trial.medpath.com/news/d38e397482028c62/cidara-s-phase-ii-trial-testing-cd388-for-flu-prevention-fully-enrolled-with-5000-subjects 2024-12-04T16:51:57+00:00 weekly 0.7 https://trial.medpath.com/news/308a924842be4faa/early-detection-and-interception-research-shows-promise-at-ash 2024-12-04T16:44:20+00:00 weekly 0.7 https://trial.medpath.com/news/b1767c275ed9a3cd/antag-therapeutics-secures-eur80-million-in-weight-loss-therapy-financing-pharmatimes 2024-12-04T16:12:38+00:00 weekly 0.7 https://trial.medpath.com/news/4f7ce172c6f96798/real-world-data-and-patient-planning-can-keep-trials-from-collapsing-clinical-trials-arena 2024-12-04T16:11:38+00:00 weekly 0.7 https://trial.medpath.com/news/2a92d79d0d1e9cae/l-arginine-shows-potential-in-treating-spinocerebellar-ataxia-type-6-news-medical 2024-12-04T16:03:16+00:00 weekly 0.7 https://trial.medpath.com/news/b06bc95308c7f6af/stent-omission-after-ureteroscopy-and-lithotripsy-soul-in-the-michigan-urological-trials 2024-12-04T15:33:41+00:00 weekly 0.7 https://trial.medpath.com/news/7ccc8916fd472f20/texas-cardiac-arrhythmia-institute-at-st-david-s-medical-center-first-in-u-s-to-use-fda 2024-12-04T15:26:59+00:00 weekly 0.7 https://trial.medpath.com/news/9a9a5ac5adb0d328/ocrelizumab-in-early-stage-relapsing-remitting-multiple-sclerosis-the-phase-iiib-pubmed 2024-12-04T14:53:16+00:00 weekly 0.7 https://trial.medpath.com/news/93776cdc4afad2ba/tribe-clinical-research-launches-new-drug-trial-focused-on-alzheimer-s-prevention 2024-12-04T14:47:12+00:00 weekly 0.7 https://trial.medpath.com/news/671fd65a62a92b13/sonnet-biotherapeutics-unveils-breakthrough-cancer-drug-delivery-system-in-major-publication 2024-12-04T14:27:04+00:00 weekly 0.7 https://trial.medpath.com/news/3132f3e2d38a4a13/vivavision-to-advance-non-steroidal-therapy-in-phase-iii-following-phase-ii-win 2024-12-04T14:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/596eda3342f6f656/arrowhead-seeks-approval-to-begin-rnai-therapy-trial-for-obesity-treatment 2024-12-04T14:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/f208b3020663bef8/omniscience-inc-and-inmune-bio-inc-partner-to-accelerate-a-phase-2-alzheimer-s-trial 2024-12-04T14:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/5886360c41fb9e5e/idiopathic-pulmonary-fibrosis-promising-drugs-foxo3-and-beyond-labiotech 2024-12-04T14:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/8610c128ea6e00d8/daratumumab-quadruplet-improves-outcomes-in-transplant-ineligible-myeloma 2024-12-04T14:11:05+00:00 weekly 0.7 https://trial.medpath.com/news/153a3e764f93ea19/study-shows-comparable-safety-efficacy-of-idecabtagene-vicleucel-in-older-patients 2024-12-04T14:07:34+00:00 weekly 0.7 https://trial.medpath.com/news/aa5775cac2eaf110/tcbp-provides-quarterly-update-on-the-achieve-uk-clinical-trial-pr-newswire 2024-12-04T13:31:02+00:00 weekly 0.7 https://trial.medpath.com/news/f7e7efbdd76b8b6a/adaptive-research-welcomes-western-radiation-oncology-to-globenewswire 2024-12-04T13:25:03+00:00 weekly 0.7 https://trial.medpath.com/news/b0b7ab0a8a3b9336/outlook-therapeutics-r-announces-nice-recommendation-of-lytenavatm-bevacizumab 2024-12-04T13:25:03+00:00 weekly 0.7 https://trial.medpath.com/news/8f734a4816063f0b/ensysce-biosciences-announces-strategic-partnership-for-the-development-and-yahoo-finance 2024-12-04T13:22:41+00:00 weekly 0.7 https://trial.medpath.com/news/7a76c4b505d1f14b/windtree-announces-partnership-with-new-growth-advisors-to-leverage-positive-phase-2 2024-12-04T13:18:26+00:00 weekly 0.7 https://trial.medpath.com/news/1e5cebd4de4ec68e/zepbound-bests-wegovy-for-weight-loss-in-new-trial 2024-12-04T13:12:48+00:00 weekly 0.7 https://trial.medpath.com/news/b2ee237d255f14ac/egetis-has-decided-to-explore-rth-beta-as-the-next-indication-for-tiratricol-emcitate-r 2024-12-04T13:02:12+00:00 weekly 0.7 https://trial.medpath.com/news/54e6fdfce1216f25/treovir-announces-opening-of-g207-phase-2-clinical-trial-in-children-with-recurrent-brain-tumors 2024-12-04T12:48:14+00:00 weekly 0.7 https://trial.medpath.com/news/9032bcb2d0827357/allay-therapeutics-receives-fda-breakthrough-therapy-designation-btd-for-atx101-for 2024-12-04T12:42:34+00:00 weekly 0.7 https://trial.medpath.com/news/86814070e794fe31/amylyx-pharmaceuticals-announces-pivotal-phase-3-lucidity-trial-design-for-yahoo-finance 2024-12-04T12:37:56+00:00 weekly 0.7 https://trial.medpath.com/news/efb5b595dbfed157/relmada-therapeutics-reports-that-data-monitoring-committee-globenewswire 2024-12-04T12:33:57+00:00 weekly 0.7 https://trial.medpath.com/news/f0b2bb30fff55c45/atea-reports-high-efficacy-in-phase-2-hcv-treatment-study-investing-com 2024-12-04T12:24:40+00:00 weekly 0.7 https://trial.medpath.com/news/686f550ef373e190/the-multiple-myeloma-research-foundation-mmrf-announces-the-first-patient-enrolled 2024-12-04T12:23:46+00:00 weekly 0.7 https://trial.medpath.com/news/fe3f7015acae4042/teva-s-phase-3-study-of-ajovy-shows-superior-efficacy-in-migraine-prevention-for-children 2024-12-04T12:17:37+00:00 weekly 0.7 https://trial.medpath.com/news/3dab7e25eb303390/all-three-projects-powered-by-quera-computing-contributions-move-to-phase-two-of 2024-12-04T12:15:14+00:00 weekly 0.7 https://trial.medpath.com/news/4dd00d9af9c77079/stoke-therapeutics-secures-fda-breakthrough-status-for-revolutionary-dravet-syndrome-treatment 2024-12-04T12:10:41+00:00 weekly 0.7 https://trial.medpath.com/news/7189b08d3679c96d/tiziana-life-sciences-expands-breakthrough-ms-drug-trial-to-elite-u-s-medical-centers 2024-12-04T12:10:36+00:00 weekly 0.7 https://trial.medpath.com/news/43ac0618ed8d972c/first-single-dose-medicine-for-p-vivax-malaria-prequalified-by-who-and-included-in-who-guidelines 2024-12-04T12:10:34+00:00 weekly 0.7 https://trial.medpath.com/news/f63079ee0d12bf79/study-published-in-the-new-england-journal-of-medicine-ai-concludes-that-the-sepsis 2024-12-04T12:08:40+00:00 weekly 0.7 https://trial.medpath.com/news/fa2dadf9aecc0dd0/astro-survey-reveals-devastating-impact-of-prior-authorization-delays-on-cancer-care 2024-12-04T11:17:28+00:00 weekly 0.7 https://trial.medpath.com/news/27c81f2a3348ddd8/genes-highlight-who-ll-benefit-from-multiple-myeloma-therapy 2024-12-04T11:12:35+00:00 weekly 0.7 https://trial.medpath.com/news/a2a632571e607433/high-dose-vitamin-d-supplements-won-t-prevent-diabetes-in-healthy-seniors 2024-12-04T11:12:04+00:00 weekly 0.7 https://trial.medpath.com/news/96e0603f8ad85b71/stroke-combatting-drug-developed-by-nanjing-firms-obtains-fda-approval-the-nanjinger 2024-12-04T11:10:06+00:00 weekly 0.7 https://trial.medpath.com/news/96006d19747088fd/mohamad-baker-berjaoui-md-on-water-and-water-ii-findings-in-bph-urology-times 2024-12-04T11:04:34+00:00 weekly 0.7 https://trial.medpath.com/news/88fcfc922cb8ce25/a-decade-of-incremental-advances-in-radiopharmaceuticals-a-promising-future-ahead 2024-12-04T10:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/4f80c3818f02db42/gate-neurosciences-and-pitt-commence-antidepressant-drug-trial-clinical-trials-arena 2024-12-04T09:46:16+00:00 weekly 0.7 https://trial.medpath.com/news/ff4fbc06a346c3b4/prospective-study-of-patient-nursing-and-oncology-provider-perspectives-on-telemedicine 2024-12-04T08:41:09+00:00 weekly 0.7 https://trial.medpath.com/news/ba49facbb2be7730/leo-pharma-s-growth-hope-receives-approval-in-the-uk-medwatch 2024-12-04T08:31:56+00:00 weekly 0.7 https://trial.medpath.com/news/543ce224ce788888/metabolic-and-endocrine-therapies-could-star-among-us-fda-s-last-2024-approvals 2024-12-04T07:55:11+00:00 weekly 0.7 https://trial.medpath.com/news/bb4acfe8196d4b32/cytokinetics-announces-start-of-comet-hf-a-confirmatory-phase-3-clinical-trial-of-biospace 2024-12-04T07:31:03+00:00 weekly 0.7 https://trial.medpath.com/news/d46cfb0026ef6362/beyond-cancer-ltd-announces-phase-1b-clinical-trial-approval-for-lv-uno-in-barchart-com 2024-12-04T07:27:43+00:00 weekly 0.7 https://trial.medpath.com/news/f7e22738e3b6cff4/fda-grants-orphan-drug-designation-to-rezolute-s-ersodetug-rz358-for-the-biospace 2024-12-04T07:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/43996fb75330ce46/a-new-hope-for-atrial-fibrillation-patients-with-breakthrough-catheter-technology 2024-12-04T07:20:59+00:00 weekly 0.7 https://trial.medpath.com/news/1cd4f5a40e6be099/lupus-nephritis-clinical-trial-pipeline-experiences-momentum-delveinsight-estimates-a 2024-12-04T07:05:14+00:00 weekly 0.7 https://trial.medpath.com/news/2554601cef6bd0c3/medical-breakthrough-as-therapy-unveiled-for-untreatable-debilitating-illness-express-co-uk 2024-12-04T06:02:02+00:00 weekly 0.7 https://trial.medpath.com/news/47b705617aafc32a/nmpa-grants-conditional-approval-to-fruquintinib-plus-sintilimab-for-pmmr-endometrial-cancer 2024-12-04T05:26:19+00:00 weekly 0.7 https://trial.medpath.com/news/2781919d1620a52a/can-the-girl-power-of-arrivo-s-depression-drug-help-reverse-its-fortunes-pharmavoice 2024-12-04T05:25:12+00:00 weekly 0.7 https://trial.medpath.com/news/2cd410c05e627559/alterity-completes-phase-2-trial-in-multiple-system-atrophy-finance-news-network 2024-12-04T05:14:58+00:00 weekly 0.7 https://trial.medpath.com/news/5f4fdfaabe2136ef/protein-conformation-may-have-a-hand-in-herpes-drug-resistance-drug-discovery-news 2024-12-04T05:05:55+00:00 weekly 0.7 https://trial.medpath.com/news/24e9024308ae48c3/clinical-trial-of-aptamer-based-liver-cancer-drug-to-begin-at-4-korean-hospitals-kbr 2024-12-04T04:52:54+00:00 weekly 0.7 https://trial.medpath.com/news/de36b25e979e5ec5/power-metals-test-work-produces-high-grade-cesium-concentrate-of-19-97 2024-12-04T03:48:45+00:00 weekly 0.7 https://trial.medpath.com/news/299554f44d686a7a/innocare-urologics-wins-fda-nod-for-urinary-safety-catheter-massdevice 2024-12-04T03:37:19+00:00 weekly 0.7 https://trial.medpath.com/news/9ca2caaa631f8aee/dr-kalinsky-on-the-postmonarch-study-in-hr-her2-advanced-breast-cancer-onclive 2024-12-04T03:11:19+00:00 weekly 0.7 https://trial.medpath.com/news/79b36a617e9ead1a/pd-1-inhibitors-make-impact-in-merkel-cell-carcinoma-but-unmet-needs-persist-onclive 2024-12-04T02:57:45+00:00 weekly 0.7 https://trial.medpath.com/news/5346d6f35523ed4b/empowering-patients-exploring-self-administration-of-rozanolixizumab-for-myasthenia-gravis 2024-12-04T02:11:00+00:00 weekly 0.7 https://trial.medpath.com/news/11042d24fb7a7d62/clinical-trial-expert-warns-against-poor-record-keeping-risks-at-oncology-conference 2024-12-04T02:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/a69ef7c3e35ab4c8/fda-s-december-calendar-features-nine-pdufa-dates 2024-12-04T01:51:35+00:00 weekly 0.7 https://trial.medpath.com/news/77fb80e1f7d6cba1/mysterious-disease-outbreak-claims-143-lives-in-southwest-congo 2024-12-04T01:21:32+00:00 weekly 0.7 https://trial.medpath.com/news/310e17c940f49e2a/icon-launches-comprehensive-patient-centric-outcome-measures-solution-for-clinical-trials 2024-12-04T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/de3da053ac5ad588/disitamab-vedotin-shows-early-efficacy-in-her2-expressing-breast-cancer-with-pam 2024-12-04T00:55:29+00:00 weekly 0.7 https://trial.medpath.com/news/13ce499256c534c8/first-of-its-kind-gene-editing-treatment-saves-baby-with-rare-genetic-disorder 2024-12-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b9a24038cd52d787/astrazeneca-initiates-first-in-human-phase-i-trial-for-novel-investigational-drug-d9440c00001 2024-12-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8fb72113de69f9ba/sudo-biosciences-begins-trial-of-drug-candidate-for-neuroinflammatory-conditions 2024-12-03T23:31:53+00:00 weekly 0.7 https://trial.medpath.com/news/6d64a0ce43d9b229/theratechnologies-announces-resumed-production-of-egrifta-sv-stock-titan 2024-12-03T21:50:33+00:00 weekly 0.7 https://trial.medpath.com/news/c49af5a42f730319/why-does-the-approval-of-the-vaccine-take-longer-in-the-eu-telegraph-telegrafi 2024-12-03T21:46:14+00:00 weekly 0.7 https://trial.medpath.com/news/1fc4bc68dd46becf/outlook-therapeutics-r-announces-executive-leadership-transition-quantisnow 2024-12-03T21:45:07+00:00 weekly 0.7 https://trial.medpath.com/news/7bcd14178ab2a5af/trevi-therapeutics-nalbuphine-shows-breakthrough-abuse-resistance-in-key-clinical-study 2024-12-03T21:25:27+00:00 weekly 0.7 https://trial.medpath.com/news/da8da589ad92a9a8/uc-san-diego-and-scripps-research-join-national-team-to-make-vision-restoring-whole 2024-12-03T20:56:18+00:00 weekly 0.7 https://trial.medpath.com/news/fbdee412d64f177b/systematic-review-shows-favorable-functional-histological-findings-for-givinostat-in 2024-12-03T20:17:39+00:00 weekly 0.7 https://trial.medpath.com/news/d7e21998661b851c/suo-2024-emerging-perioperative-systemic-therapy-urotoday 2024-12-03T20:05:47+00:00 weekly 0.7 https://trial.medpath.com/news/70d31766bc1ceb70/medipost-inc-expands-u-s-presence-with-key-executive-appointments-advances-biospace 2024-12-03T19:43:14+00:00 weekly 0.7 https://trial.medpath.com/news/47383c0b2eb0657c/markedly-fewer-cf-lung-transplants-since-trikafta-approval-study 2024-12-03T19:29:11+00:00 weekly 0.7 https://trial.medpath.com/news/bcfc5c9c32451f63/oncolytics-biotech-r-reports-completion-of-initial-safety-phase-enrollment-for-goblet-biospace 2024-12-03T19:05:38+00:00 weekly 0.7 https://trial.medpath.com/news/bca4f2c137886a47/maze-therapeutics-115-million-series-d-raised-to-develop-precision-medicine 2024-12-03T19:04:01+00:00 weekly 0.7 https://trial.medpath.com/news/7ecc57fde101fe7e/vir-has-positive-readthrough-from-janux-data-says-morgan-stanley-markets-insider 2024-12-03T18:44:37+00:00 weekly 0.7 https://trial.medpath.com/news/5603fbbde771232b/irlab-s-patient-recruitment-for-pirepemat-study-slower-than-expected-marketscreener 2024-12-03T18:43:24+00:00 weekly 0.7 https://trial.medpath.com/news/bb179a87c8822b56/three-professors-become-overnight-millionaires-after-a-major-breakthrough-in-medicine-for 2024-12-03T18:32:49+00:00 weekly 0.7 https://trial.medpath.com/news/bdbdd7fb9a399fc6/u-s-renal-care-enrolled-first-patients-in-the-voice-collaborative-clinical-trial-of-vafseo 2024-12-03T18:02:38+00:00 weekly 0.7 https://trial.medpath.com/news/36ad88e3e057c28f/augustana-college-offering-fda-approved-tinnitus-treatment-device-river-cities-reader 2024-12-03T17:53:44+00:00 weekly 0.7 https://trial.medpath.com/news/9ab4ef41d8307c66/hansoh-pharmaceutical-group-company-limited-regulator-grants-breakthrough-therapy 2024-12-03T17:33:28+00:00 weekly 0.7 https://trial.medpath.com/news/10c7fd26a1586ead/fda-authorizes-predetermined-change-control-plan-for-sleep-wearable-dreem-3s 2024-12-03T17:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/e20e93877d4b2b12/new-multi-society-guidance-most-patients-can-continue-glp-1-ras-before-endoscopic-procedures 2024-12-03T17:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/920ce05ecfaa8728/trials-launch-of-nadofaragene-firadenovec-in-bladder-cancer-urology-times 2024-12-03T16:54:36+00:00 weekly 0.7 https://trial.medpath.com/news/e8eb6cb72bd900c0/viewpoint-closing-the-gap-in-pediatric-drug-research-missoula-current 2024-12-03T16:41:20+00:00 weekly 0.7 https://trial.medpath.com/news/e3bdb627f3da9efc/university-hospitals-awarded-7-million-by-pcori-to-study-endovascular-thrombectomy-in 2024-12-03T16:25:30+00:00 weekly 0.7 https://trial.medpath.com/news/a976fdb123ec2727/janux-impresses-wall-street-with-new-prostate-cancer-drug-results-biopharma-dive 2024-12-03T16:18:43+00:00 weekly 0.7 https://trial.medpath.com/news/f10ca73a527c5bec/lantern-pharma-shares-rise-after-fast-track-designation-for-cancer-treatment 2024-12-03T15:46:26+00:00 weekly 0.7 https://trial.medpath.com/news/08a7ab2b6b21ceb8/perioperative-nivolumab-results-in-favourable-long-term-outcomes-in-patients-with-locally-nature 2024-12-03T15:45:33+00:00 weekly 0.7 https://trial.medpath.com/news/5bf61ee6fac982ee/alligator-bioscience-s-operating-loss-increased-looking-forward-to-important-year 2024-12-03T15:45:18+00:00 weekly 0.7 https://trial.medpath.com/news/7a3c01ae6a90fa20/pcori-awards-unc-researcher-14-4-million-to-study-emerging-medications-for-pibd-patients 2024-12-03T15:40:15+00:00 weekly 0.7 https://trial.medpath.com/news/b9ca26edac6b01d0/takeda-puts-over-1-1b-on-the-line-for-keros-blood-cancer-anemia-drug-biospace 2024-12-03T15:07:02+00:00 weekly 0.7 https://trial.medpath.com/news/148067e08951cc9c/active-biotech-reduces-loss-slightly-projects-progressing-according-to-plan 2024-12-03T14:52:16+00:00 weekly 0.7 https://trial.medpath.com/news/3d4fa16cd3380254/clinical-trials-in-aml-seek-to-eliminate-leftover-cells-that-persist-after-treatment 2024-12-03T14:34:58+00:00 weekly 0.7 https://trial.medpath.com/news/6866427d993b654b/dana-farber-researchers-to-present-findings-at-2024-san-antonio-breast-cancer-symposium 2024-12-03T14:34:48+00:00 weekly 0.7 https://trial.medpath.com/news/dd2384923d7102df/chinese-bio-tech-sector-thrives-with-record-breaking-exports-and-key-fda-approvals 2024-12-03T14:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/f6d98b9eea91ca5c/ferring-advances-three-studies-in-adstiladrin-r-nadofaragene-firadenovec-vncg 2024-12-03T14:12:40+00:00 weekly 0.7 https://trial.medpath.com/news/ec83de2750bf6105/effects-of-initial-peritoneal-dialysis-prescription-on-clinical-outcomes-in-japanese-nature 2024-12-03T14:12:34+00:00 weekly 0.7 https://trial.medpath.com/news/9a4705c31dd44c00/wave-neuroscience-receives-fda-breakthrough-device-designation-for-pioneering-ptsd 2024-12-03T14:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/8a4bdb97e7d5e3f7/va-awards-1-5-million-to-study-using-psychedelics-for-ptsd-treatment-air-force-times 2024-12-03T14:05:08+00:00 weekly 0.7 https://trial.medpath.com/news/1f13e8135ede289d/achieve-life-sciences-gets-fda-green-light-for-landmark-vaping-cessation-drug-trial 2024-12-03T14:00:39+00:00 weekly 0.7 https://trial.medpath.com/news/bd64690b5536c19c/amarna-therapeutics-partners-with-northx-biologics-to-advance-nimvec-am510-gene-therapy-for-type-1-diabetes 2024-12-03T14:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3ff50305db1d2a90/gilead-plots-adc-comeback-with-potential-465m-license-agreement-biospace 2024-12-03T13:57:08+00:00 weekly 0.7 https://trial.medpath.com/news/84a9d56e45d3516d/sk-bioscience-wins-appeal-against-pfizer-in-pneumococcal-vaccine-patent-dispute 2024-12-03T13:55:25+00:00 weekly 0.7 https://trial.medpath.com/news/1ea0b435c33a80f4/kairos-pharma-adds-city-of-hope-cancer-center-for-phase-2-env105-clinical-trial 2024-12-03T13:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/fb99538ee5ae408c/saol-therapeutics-announces-submission-of-new-drug-application-nda-to-the-u-s-fda 2024-12-03T13:31:29+00:00 weekly 0.7 https://trial.medpath.com/news/ed107b2cabbd3268/gland-pharma-receives-us-fda-approval-for-generic-xalatan-pharmabiz-com 2024-12-03T13:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/f87feca52c6ccbd5/karyopharm-therapeutics-provides-endometrial-cancer-program-update-dec-3-2024 2024-12-03T13:21:10+00:00 weekly 0.7 https://trial.medpath.com/news/3949bb5cca22699e/lantern-pharma-s-investigational-drug-candidate-lp-184-receives-second-fast-track 2024-12-03T13:18:10+00:00 weekly 0.7 https://trial.medpath.com/news/bb496c68a5f8cc8e/polaritybio-announces-interim-enrollment-achieved-in-skinte-s-phase-iii-pivotal-study 2024-12-03T13:14:55+00:00 weekly 0.7 https://trial.medpath.com/news/c3e4a5f066191f9b/relay-therapeutics-inks-500m-licensing-deal-with-elevar-for-cancer-drug-lirafugratinib 2024-12-03T13:10:08+00:00 weekly 0.7 https://trial.medpath.com/news/b9b8ec75f71e965e/pds-biotech-to-host-key-opinion-leader-event-on-december-17-globenewswire 2024-12-03T13:04:57+00:00 weekly 0.7 https://trial.medpath.com/news/dd58a5e34fa4e629/cancer-survivorship-care-faces-critical-gaps-in-long-term-patient-monitoring-and-transition-management 2024-12-03T13:00:10+00:00 weekly 0.7 https://trial.medpath.com/news/0e9108c20f1ee904/kinevant-sciences-announces-topline-results-from-phase-2-resolve-lung-study-of-biospace 2024-12-03T12:58:16+00:00 weekly 0.7 https://trial.medpath.com/news/0b544c14a0dc9fff/intra-cellular-therapies-submits-supplemental-new-drug-application-snda-to-fda-for 2024-12-03T12:36:41+00:00 weekly 0.7 https://trial.medpath.com/news/3e355e547ea2c061/psyence-biomedical-advances-phase-iib-trial-doubles-psylabs-stake-value-to-2m 2024-12-03T12:34:38+00:00 weekly 0.7 https://trial.medpath.com/news/6be98fbf557f6af3/aptose-partners-with-nci-to-advance-tuspetinib-cancer-treatment-in-clinical-trials 2024-12-03T12:34:36+00:00 weekly 0.7 https://trial.medpath.com/news/d4fb3cb6f013eb55/merus-s-swot-analysis-innovative-antibody-stock-shows-promise-amid-clinical-trials 2024-12-03T12:29:58+00:00 weekly 0.7 https://trial.medpath.com/news/e1f257e17dfdd692/tonix-pharmaceuticals-holding-corp-filed-sec-form-8-k-regulation-fd-disclosure-other 2024-12-03T12:19:53+00:00 weekly 0.7 https://trial.medpath.com/news/53e0cfe808ae671f/key-stability-testing-milestones-achieved-for-mrx1-company-announcement-investegate 2024-12-03T12:09:42+00:00 weekly 0.7 https://trial.medpath.com/news/5433cb56f175b90a/corbus-pharma-secures-fda-fast-track-status-for-cancer-drug-crb-701-crbp-stock-news 2024-12-03T12:05:56+00:00 weekly 0.7 https://trial.medpath.com/news/718ef301f566f88e/elicio-therapeutics-announces-completion-of-phase-2-amplify-7p-study-enrollment 2024-12-03T12:04:42+00:00 weekly 0.7 https://trial.medpath.com/news/369b34e5aa699ad5/valneva-reports-positive-three-year-antibody-persistence-data-for-its-single-shot 2024-12-03T12:01:50+00:00 weekly 0.7 https://trial.medpath.com/news/923488de50252e38/datroway-r-datopotamab-deruxtecan-receives-eu-approval-for-previously-treated-metastatic-hr-her2-breast-cancer 2024-12-03T11:54:30+00:00 weekly 0.7 https://trial.medpath.com/news/991124240e341a7e/cartesian-advances-mg-treatment-with-phase-3-trial-plans-investing-com 2024-12-03T11:18:24+00:00 weekly 0.7 https://trial.medpath.com/news/eb55a320c41dd9f3/deep-brain-stimulation-helps-two-patients-walk-after-spinal-cord-injury 2024-12-03T11:12:59+00:00 weekly 0.7 https://trial.medpath.com/news/9f56fbe3943c510e/artery-procedure-may-offer-surgery-free-way-to-ease-knee-arthritis 2024-12-03T11:12:03+00:00 weekly 0.7 https://trial.medpath.com/news/5b35c5238d0140a5/genethon-and-hansa-biopharma-announce-initiation-of-a-phase-2-trial-of-imlifidase-as-biospace 2024-12-03T11:11:57+00:00 weekly 0.7 https://trial.medpath.com/news/2a120334c27b754d/polyactiva-s-pa5108-glaucoma-implant-shows-promising-results-in-clinical-trial-paving-the 2024-12-03T11:09:18+00:00 weekly 0.7 https://trial.medpath.com/news/37e737606a44c76a/inventisbio-announces-positive-phase-2-study-results-for-d-2570-tyk2-inhibitor-in-biospace 2024-12-03T10:47:51+00:00 weekly 0.7 https://trial.medpath.com/news/6acd30dc84672c61/can-dermata-s-dmt310-clear-the-phase-iii-acne-trial-rttnews 2024-12-03T10:46:56+00:00 weekly 0.7 https://trial.medpath.com/news/c17e1f83454ce4b4/resalis-therapeutics-announces-initiation-of-phase-1-clinical-trial-for-res-010-in-obesity 2024-12-03T10:45:51+00:00 weekly 0.7 https://trial.medpath.com/news/b1487ac279f8c177/gene-therapy-and-secondary-malignancies-integration-site-analysis-can-only-be-part-of 2024-12-03T10:30:43+00:00 weekly 0.7 https://trial.medpath.com/news/dc7fcdba509df53c/hutchmed-innovent-win-china-approval-for-breakthrough-cancer-drug-combination-stock-titan 2024-12-03T10:13:47+00:00 weekly 0.7 https://trial.medpath.com/news/8b401a32c9d1e765/japan-s-health-ministry-panel-gives-greenlight-to-new-als-drug 2024-12-03T10:02:59+00:00 weekly 0.7 https://trial.medpath.com/news/d9ab0fa679eef25f/eye-cancer-breakthrough-as-nhs-roll-out-new-pioneering-drug-which-could-boost-patients 2024-12-03T09:58:29+00:00 weekly 0.7 https://trial.medpath.com/news/436e3ae732f4494b/fda-s-ban-on-flavored-e-cigarettes-faces-supreme-court-challenge-amid-youth-protection-concerns 2024-12-03T09:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/860d5bfb4ddd1118/shanghai-henlius-boosts-oncology-portfolio-with-drug-approval-tipranks-com 2024-12-03T09:47:11+00:00 weekly 0.7 https://trial.medpath.com/news/b8befc5e7e6868da/sunshine-biopharma-announces-breakthrough-research-results-on-the-company-s-k1-1 2024-12-03T09:09:44+00:00 weekly 0.7 https://trial.medpath.com/news/f6ff7a5ecdcb74af/jasper-therapeutics-announces-first-patient-dosed-in-phase-1b-2a-etesian-clinical-study 2024-12-03T08:51:39+00:00 weekly 0.7 https://trial.medpath.com/news/bc50317014e17c53/shockwave-medical-s-ivl-technology-still-safe-effective-in-patients-with-calcified-nodules 2024-12-03T08:42:57+00:00 weekly 0.7 https://trial.medpath.com/news/ac6e40cb4d8b1ac1/sanofi-korea-to-launch-beyfortus-for-rsv-prevention-in-infants-early-next-year-kbr 2024-12-03T08:37:37+00:00 weekly 0.7 https://trial.medpath.com/news/bd8cee5d3504840c/patient-relevant-digital-motor-outcomes-for-clinical-trials-in-hereditary-spastic-paraplegia-type-7 2024-12-03T08:06:56+00:00 weekly 0.7 https://trial.medpath.com/news/9ca367199862969c/sobi-s-strength-in-haematology-to-be-showcased-at-ash-2024 2024-12-03T07:30:33+00:00 weekly 0.7 https://trial.medpath.com/news/2a8db1c8c22c4484/efficacy-of-vyepti-highlighted-by-new-clinical-trial-results-in-severe-migraine-cision-news 2024-12-03T07:20:27+00:00 weekly 0.7 https://trial.medpath.com/news/f3d35dc19b316266/simcere-s-sublingual-edaravone-nears-international-phase-iii-trial-after-china-approval 2024-12-03T07:03:38+00:00 weekly 0.7 https://trial.medpath.com/news/e31ca39d4a776275/cdc-reports-significant-progress-in-sti-control-gonorrhea-cases-drop-7-first-major-syphilis-decline-in-20-years 2024-12-03T06:58:00+00:00 weekly 0.7 https://trial.medpath.com/news/47e3d3ecb92debc7/microbiome-research-facilities-at-duchossois-family-institute-set-to-begin-drug-testing-by-january 2024-12-03T05:15:47+00:00 weekly 0.7 https://trial.medpath.com/news/c7a6fa5fb545fa59/jupiter-neurosciences-juns-raises-11-million-in-first-ipo-of-december-2024-iposcoop 2024-12-03T04:24:57+00:00 weekly 0.7 https://trial.medpath.com/news/209cc8e5e3fbdc89/precision-medicine-transforming-treatment-for-corneal-blindness-mirage-news 2024-12-03T03:21:20+00:00 weekly 0.7 https://trial.medpath.com/news/9b04798c7e5d7c18/avera-to-expand-cancer-research-in-marshall-region-news-sports-jobs 2024-12-03T02:50:52+00:00 weekly 0.7 https://trial.medpath.com/news/7aea81b1b22fd791/acceptance-of-a-new-drug-application-for-the-gram-negative-bacterial-infection-treatment 2024-12-03T02:33:33+00:00 weekly 0.7 https://trial.medpath.com/news/e5570762d6dd8834/invion-doses-first-patient-in-phase-i-ii-non-melanoma-skin-cancer-trial-inn 2024-12-03T02:29:35+00:00 weekly 0.7 https://trial.medpath.com/news/f1a9779f3499d1f6/what-s-it-like-to-be-in-a-clinical-trial-abbott-newsroom 2024-12-03T02:01:32+00:00 weekly 0.7 https://trial.medpath.com/news/34a63cca4eae93cc/novelmed-receives-fda-ind-approval-for-nm8074-globenewswire 2024-12-03T01:31:39+00:00 weekly 0.7 https://trial.medpath.com/news/c3f4683cbe714d46/a-phase-2-study-of-nivolumab-and-ipilimumab-immunotherapy-with-or-without 2024-12-03T01:25:57+00:00 weekly 0.7 https://trial.medpath.com/news/1bc8aa6bd68ad575/ormp-preparations-for-new-phase-3-trial-advance-while-ormp-leverages-balance 2024-12-03T01:14:28+00:00 weekly 0.7 https://trial.medpath.com/news/764bb631a5ee5c58/the-landscape-of-recurrent-spontaneous-abortion-registered-on-clinical-trials-gov 2024-12-03T01:04:16+00:00 weekly 0.7 https://trial.medpath.com/news/ab136e2e929ba24e/closing-bell-asx-gallops-as-healthcare-sector-jumps-led-by-invion 2024-12-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/693f79c566c169ce/diamyd-medical-secures-sek-114-million-through-rights-issue-to-advance-type-1-diabetes-therapy 2024-12-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6dac0bff9d857682/novo-nordisk-to-present-new-data-highlighting-innovative-rare-blood 2024-12-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/76768636b9bf8811/eu-gmp-annex-1-revision-stricter-standards-for-sterile-medicinal-products-now-in-effect 2024-12-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b5c951242059d53f/lixte-biotechnology-inks-amendment-to-cancer-drug-study-agreement-investing-com 2024-12-02T23:44:39+00:00 weekly 0.7 https://trial.medpath.com/news/3f6b80bd2cc16402/ocumension-advances-phase-iii-trials-for-key-drug-tipranks-com 2024-12-02T23:40:55+00:00 weekly 0.7 https://trial.medpath.com/news/30ab0ca19f18ba3b/ptc-gets-1bn-from-novartis-for-phase-ii-huntington-s-candidate-citeline 2024-12-02T23:08:22+00:00 weekly 0.7 https://trial.medpath.com/news/158f504bbb3fa65e/serina-therapeutics-secures-10m-financing-for-parkinson-s-drug-trial-at-120-premium 2024-12-02T22:35:37+00:00 weekly 0.7 https://trial.medpath.com/news/c8afbb166870c4ec/raider-trial-safety-of-tumor-directed-dose-escalation-robert-huddart-urotoday 2024-12-02T22:18:11+00:00 weekly 0.7 https://trial.medpath.com/news/eef57dc1101afc22/study-identifies-strategies-for-racial-ethnic-diversity-in-clinical-trials-healio 2024-12-02T22:14:23+00:00 weekly 0.7 https://trial.medpath.com/news/25641dc4d0363569/janux-announces-doses-selected-for-phase-1b-expansion-trials-supported-by-markets-data 2024-12-02T21:51:46+00:00 weekly 0.7 https://trial.medpath.com/news/d646f22fe510096f/eisai-closes-door-on-lorcaserin-program-for-dravet-syndrome-neurologylive 2024-12-02T20:11:06+00:00 weekly 0.7 https://trial.medpath.com/news/e7fa3cc0594e4697/gemcitabine-and-docetaxel-combination-offers-promising-alternative-to-bcg-in-bladder 2024-12-02T20:01:18+00:00 weekly 0.7 https://trial.medpath.com/news/3d35648756e4967f/foundation-fighting-blindness-partners-with-university-of-colorado-anschutz-medical 2024-12-02T19:51:02+00:00 weekly 0.7 https://trial.medpath.com/news/a52b95c28b8013b0/china-medical-system-gained-exclusive-commercialization-globenewswire 2024-12-02T19:43:49+00:00 weekly 0.7 https://trial.medpath.com/news/e4f18f5d35ed4d9c/from-dogs-to-humans-ai-powered-drug-response-prediction-technology-demonstrates 2024-12-02T19:36:30+00:00 weekly 0.7 https://trial.medpath.com/news/93e30847d9d5f187/summit-therapeutics-stock-set-to-soar-by-mid-2025-on-harmoni-phase-3-trial 2024-12-02T19:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/5e436079c9e4b3e3/novartis-ptc-ink-up-to-2-9b-huntington-s-disease-collaboration 2024-12-02T19:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/f76e06ea6a4830b2/fox-chase-s-study-activation-unit-showcases-work-in-clinical-research-innovation-at 2024-12-02T18:53:07+00:00 weekly 0.7 https://trial.medpath.com/news/40bb61f1dd555b32/batten-1-may-preserve-vision-with-juvenile-batten-disease-scientists 2024-12-02T18:13:43+00:00 weekly 0.7 https://trial.medpath.com/news/340c10676692b0c1/clinical-trial-of-bovhyaluronidase-azoximer-raises-hopes-for-patients-with-pulmonary 2024-12-02T17:46:58+00:00 weekly 0.7 https://trial.medpath.com/news/a2ebe3cd61cdf1aa/cm24-plus-nivolumab-and-chemo-displays-efficacy-vs-chemo-alone-in-metastatic-pdac 2024-12-02T17:42:33+00:00 weekly 0.7 https://trial.medpath.com/news/9955277423fab964/intratumoral-heterogeneity-drives-acquired-therapy-resistance-in-a-patient-with-metastatic 2024-12-02T17:37:59+00:00 weekly 0.7 https://trial.medpath.com/news/09db1f35b1173cdb/year-in-review-multiple-myeloma-medpage-today 2024-12-02T17:37:10+00:00 weekly 0.7 https://trial.medpath.com/news/4334ca85c4036416/improving-hiv-aids-treatment-and-prevention-through-statistical-expertise 2024-12-02T17:18:10+00:00 weekly 0.7 https://trial.medpath.com/news/2acb8c45d795560f/biotech-stocks-facing-fda-decision-in-december-2024-rttnews 2024-12-02T17:12:27+00:00 weekly 0.7 https://trial.medpath.com/news/1b75b96925332cdb/biopharma-takes-on-deadly-brain-cancer-after-decades-of-failure-biospace 2024-12-02T17:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/9ee41c22fbf1b2b2/pain-management-collaboratory-coordinating-center-receives-grant-to-continue-research 2024-12-02T16:57:17+00:00 weekly 0.7 https://trial.medpath.com/news/376514476986503d/abingworth-tight-lipped-on-1-5bn-clinical-trials-fund-reports-citeline 2024-12-02T16:54:23+00:00 weekly 0.7 https://trial.medpath.com/news/27e475ddfa8dcffa/baseline-response-rates-inform-immunotherapy-sequencing-in-nsclc 2024-12-02T16:53:26+00:00 weekly 0.7 https://trial.medpath.com/news/62b028ec91a89cf7/oral-presentation-discussing-sozinibercept-set-for-the-annual-floretina-congress 2024-12-02T16:41:14+00:00 weekly 0.7 https://trial.medpath.com/news/904f00cfc32fafce/loma-linda-university-children-s-hospital-receives-48000-st-baldrick-s-foundation-grant 2024-12-02T16:33:39+00:00 weekly 0.7 https://trial.medpath.com/news/10f62d4e452a51f7/novocure-device-succeeds-in-pancreatic-cancer-study-fda-sets-cytokinetics-decision-date 2024-12-02T16:10:28+00:00 weekly 0.7 https://trial.medpath.com/news/2cecd28649a1e887/oncoc4-announces-fda-clearance-of-ind-application-for-potential-best-in-class-pd-1 2024-12-02T16:02:25+00:00 weekly 0.7 https://trial.medpath.com/news/c9d106a1ed4a49ff/senti-bio-s-phase-1-car-nk-data-allink-raises-42m-endpoints-news 2024-12-02T15:46:14+00:00 weekly 0.7 https://trial.medpath.com/news/096cc0f8982a6559/milk-based-therapies-could-be-coming-this-biotech-ceo-is-aiming-to-lead-the-way 2024-12-02T15:42:37+00:00 weekly 0.7 https://trial.medpath.com/news/120c7dd0fb70e992/biotech-advances-drive-cancer-research-as-global-rates-continue-upward-trend 2024-12-02T15:39:55+00:00 weekly 0.7 https://trial.medpath.com/news/693cfa4f40e813dd/senti-bio-announces-positive-initial-clinical-data-in-phase-globenewswire 2024-12-02T15:35:27+00:00 weekly 0.7 https://trial.medpath.com/news/466784e71c08321f/positive-chmp-opinion-for-the-extension-of-indication-of-palforzia-r-for-the-treatment-of-biospace 2024-12-02T15:34:01+00:00 weekly 0.7 https://trial.medpath.com/news/18d12d489aa71e4b/what-an-early-discovery-in-a-syracuse-lab-could-mean-for-late-stage-breast-cancer 2024-12-02T15:31:25+00:00 weekly 0.7 https://trial.medpath.com/news/98818a6b176b100b/expres2ion-announces-approval-to-initiate-a-phase-i-clinical-trial-of-es2b-c001-its-novel 2024-12-02T15:28:19+00:00 weekly 0.7 https://trial.medpath.com/news/f9a57e0cef80b88c/oncolysis-immunotherapy-shows-significant-data-in-prostate-cancer 2024-12-02T15:10:07+00:00 weekly 0.7 https://trial.medpath.com/news/a3bb1357539deb00/december-2-2024-nci-supported-lungsmart-trial-joins-the-nih-pragmatic-trials-collaboratory 2024-12-02T15:03:03+00:00 weekly 0.7 https://trial.medpath.com/news/b7f5caf771cd8a30/study-reveals-divergent-cancer-drug-price-trends-us-sees-post-launch-increases-while-european-prices-decline 2024-12-02T15:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/59f6d00c11fb4f0b/pet-ct-outcomes-from-a-randomised-controlled-trial-of-rosuvastatin-as-an-adjunct-to 2024-12-02T14:54:07+00:00 weekly 0.7 https://trial.medpath.com/news/023bca8934462570/ajax-therapeutics-to-present-overview-of-phase-1-clinical-trial-evaluating-aj1-11095-a 2024-12-02T14:52:57+00:00 weekly 0.7 https://trial.medpath.com/news/93ee500f4f425cbf/use-of-mesoglycan-in-the-acute-phase-of-hemorrhoidal-disease-the-chormes-study-trials 2024-12-02T14:30:58+00:00 weekly 0.7 https://trial.medpath.com/news/de438344b00ce91b/delcath-systems-announces-fda-clearance-of-ind-application-for-phase-2-clinical-trial-of 2024-12-02T14:24:24+00:00 weekly 0.7 https://trial.medpath.com/news/de200f591bce9769/nervonik-completes-first-in-human-clinical-trial-of-nerve-stimulation-technology-for 2024-12-02T14:11:52+00:00 weekly 0.7 https://trial.medpath.com/news/4a0b52c4dd1c7fe4/sana-biotechnology-announces-fast-track-designation-for-globenewswire 2024-12-02T14:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/7ae290c93c0d282a/new-rsv-drug-delivers-promising-results-in-alaska-s-yukon-kuskokwim-delta 2024-12-02T14:10:36+00:00 weekly 0.7 https://trial.medpath.com/news/d4b612615e02bbcb/kisoji-biotechnology-raises-41-million-to-advance-lead-program-into-the-clinic-pr-newswire 2024-12-02T14:03:46+00:00 weekly 0.7 https://trial.medpath.com/news/5df3ea3950a3df9f/united-health-products-files-fda-application-for-cellustat-clinical-trial-ueec-stock-news 2024-12-02T14:02:03+00:00 weekly 0.7 https://trial.medpath.com/news/e4a2a011a5dc2212/cantargia-doses-first-subject-in-expanded-part-of-can10-s-phase-i-trial 2024-12-02T13:56:22+00:00 weekly 0.7 https://trial.medpath.com/news/407ce6214e3079c2/esperion-announces-new-drug-submissions-in-canada-for-nexletol-r-bempedoic-acid 2024-12-02T13:32:16+00:00 weekly 0.7 https://trial.medpath.com/news/59ac5398a53527c6/rigel-announces-r289-granted-fast-track-designation-by-the-fda-for-lower-risk-mds 2024-12-02T13:30:34+00:00 weekly 0.7 https://trial.medpath.com/news/6463cda0f5090896/cg-oncology-to-host-conference-call-and-webcast-on-bond-003-data-on-thursday 2024-12-02T13:14:43+00:00 weekly 0.7 https://trial.medpath.com/news/122d915508ec7dff/uc-doctors-study-if-vaccines-can-prevent-lung-cancer-recurrence-wlwt 2024-12-02T13:12:59+00:00 weekly 0.7 https://trial.medpath.com/news/c3c5b5d4403e010a/a-data-driven-approach-that-could-change-mental-healthcare-in-2025-and-beyond 2024-12-02T13:12:51+00:00 weekly 0.7 https://trial.medpath.com/news/0f4c0feccad7b28f/cytokinetics-announces-fda-acceptance-of-new-drug-globenewswire 2024-12-02T13:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/de2dbb137d91af9f/revolution-medicines-reports-progress-in-cancer-drug-trials-investing-com 2024-12-02T13:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/e7aa112b172dc614/briacell-s-phase-3-cancer-trial-clears-key-safety-review-for-breast-cancer-treatment-stock-titan 2024-12-02T13:03:38+00:00 weekly 0.7 https://trial.medpath.com/news/64cdf6ae413f94b3/ocular-therapeutixtm-announces-more-than-300-subjects-randomized-in-sol-1 2024-12-02T12:50:39+00:00 weekly 0.7 https://trial.medpath.com/news/4753518cd1fbd86d/medicus-pharma-expands-bcc-treatment-trial-to-asia-pacific-after-promising-phase-1-results 2024-12-02T12:50:36+00:00 weekly 0.7 https://trial.medpath.com/news/c4fd49c89b1e9774/zai-lab-novocure-report-positive-topline-results-from-phase-3-panova-3-trial-of-rttnews 2024-12-02T12:46:38+00:00 weekly 0.7